EP1372664A1 - Traitement de d ficiences affectant les globules sanguins - Google Patents

Traitement de d ficiences affectant les globules sanguins

Info

Publication number
EP1372664A1
EP1372664A1 EP02709780A EP02709780A EP1372664A1 EP 1372664 A1 EP1372664 A1 EP 1372664A1 EP 02709780 A EP02709780 A EP 02709780A EP 02709780 A EP02709780 A EP 02709780A EP 1372664 A1 EP1372664 A1 EP 1372664A1
Authority
EP
European Patent Office
Prior art keywords
group
compound
subject
optionally substituted
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP02709780A
Other languages
German (de)
English (en)
Inventor
Clarence N. Ahlem
Christopher Reading
James Frincke
Dwight Stickney
Henry Lardy
Padma Marwah
Ashok Marwah
Patrick T. Prendergast
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harbor Biosciences Inc
Original Assignee
Hollis Eden Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/820,483 external-priority patent/US20030060425A1/en
Application filed by Hollis Eden Pharmaceuticals Inc filed Critical Hollis Eden Pharmaceuticals Inc
Priority to EP09172321A priority Critical patent/EP2135611A1/fr
Publication of EP1372664A1 publication Critical patent/EP1372664A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0025—Esters

Definitions

  • the invention relates to methods to make or use compounds, such as 16 ⁇ - bromo-3 ⁇ -hydroxy-5 ⁇ -androstane-17-one (16 ⁇ -bromoepiandrosterone or hereafter "BrEA") 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7, 16,17-tetrahydroxyandrostane, 3,17-di ydroxy- 16- haloandrostane, methyl 2,3,4-trihydroxy-1-0-(7,17-dioxoandrost-5-ene-3 ⁇ -yl)- ⁇ -D- glucopyranosiduronate and related compounds.
  • the invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia and neutropenia.
  • DHEA dehydroepiandrosterone
  • helperT cells designated Th1 in the murine system facilitate immune effector functions that are typically dominated by cell-mediated responses.
  • helper T cells designated Th2 cells facilitate immune effector functions that are typically dominated by humoral responses.
  • a vigorous Th1 response is usually desirable to help clear infections or to slow the progression of an infection.
  • Th1 response When a subject's immune response is biased to, or dominated by, a Th2-type response, the cytokines associated with the Th2 response tend to suppress the immune system's capacity to mount a vigorous Th1 response at the same time. The converse is also generally true.
  • mammalian immune responses begin to result in an increasing Th2 response, the Th1 response to the same condition tends to weaken. Insufficient Th1 responses may be associated with progression of some infections or other conditions, see, e.g., M. Clerici and G.M. Shearer, Immunol. Today 14:107-111 , 1993; M. Clerici and G.M. Shearer, Immunol. Today 15:575-581 , 1994.
  • Hemopoiesis or hematopoiesis is the formation and development of the various types of blood cells and their progenitor cells. Mature cells are found in circulation or tissues such as the lymph nodes or the thymus. Many of the stem cells that give rise to mature forms reside in the bone marrow, although some may circulate in the blood for some time. Clinical blood cell deficiencies such as thrombocytopenia, neutropenia orerythropenia can arise from causes such as impaired hemopoiesis or abnormal loss or destruction of mature or immature blood cells.
  • thrombocytopenia abnormally low platelet counts
  • Impaired production can result from causes such as chemotherapies or radiation therapies.
  • Abnormal loss of circulating platelets is often associated with autoreactive antibodies that bind to platelets and reduce their life span.
  • TP Thrombocytopenia
  • a number of treatment options are available and the selection of a treatment typically depends on the source of the disorder and its severity.
  • Treatments include administering one or more of glucocorticoid steroids (e.g., prednisone, prednisolone), human IgG antibodies, anti-Rh(D) + antibodies for Rh(D) + patients, an androgen such as danazol, vinca alkaloids (e.g., vincristine, vinblastine), thrombopoietin and immunosuppresants (e.g., azathioprine, cyclophosphamide).
  • Splenectomy is also indicated, for example when first line treatments fail.
  • the goal of treatment is typically to increase platelet counts to 20,000 mm "3 or more typically to at least about 50,000 mm "3 and to maintain these levels.
  • NP Neutropenia
  • NP Neutropenia
  • NP is considered to exist clinically when neutrophils drop to below a level considered normal. NP can arise from impaired production of neutrophil precursors or mature neutrophils, movement of neutrophils from the circulation to tissue, abnormal circulating neutrophil loss or a combination of these causes. Impaired neutrophil production can be acquired from, e.g., treatment with a cytotoxic or cytostatic drug, chemotherapy, radiation therapy or an autoimmune response.
  • NP neuropeptide -derived neuropeptide
  • patent 5,532,230, 5,8 1 ,418 and 5,846,963 discuss the capacity of 3 ⁇ -hydroxyandrost- 5-ene-17-one, its 3-sulfate derivative and other steroids to affect platelet and neutrophil aggregation or their adhesion to endothelial cells.
  • U.S. patents 4,908,358 and 4,902,681 describe the capacity of compounds such as 5 ⁇ -pregnan-3,20-dione, cortexolone, 17-hydroxyprogesterone and 16 ⁇ - methylprogesterone to inhibit the clearance of antibody-coated cells from circulation in disorders such as immune thrombocytopenic purpura or immune hemolytic anemia.
  • U.S. patent 5,859,000 describes the capacity of compounds such as 3 ⁇ ,7 ⁇ - dihydroxyandrost-5-ene-17-one and 3 ⁇ -hydroxyandrost-5-ene-17-one to reduce mast cell mediated allergic reactions.
  • U.S. patent 5,763,433 and PCT publication WO 96/35428 describe the capacity of compounds related to dehydroepiandrosterone and 16 ⁇ - halodehydroepiandrosterone to modulate immune responses and to treat conditions certain immune related conditions such as systemic lupus erythematosus.
  • U.S. patents 5,925,630, 5,939,545 and 5,962,443 describe the capacity of 19- nur-pregnane steroids, 3 ⁇ -hydroxy-5 ⁇ -pregnan-20-one and related steroids to modulate certain neurological activities such as hypothalamic function and GABA receptor activity.
  • Some proteins such as interleukin-6 (“IL-6”), erythropoietin (“EPO”) and thrombopoietin (“TPO”) have been examined for their capacity to enhance various aspects hemopoiesis, e.g., Hematology - Basic Principles and Practice, 3 rd edition, R. Hoffman, E.J. Benz Jr.
  • the present invention provides therapeutic agents and treatment methods to treat hemopoiesis deficiencies and disorders such as TP and NP.
  • the agents and methods are thus useful to reduce one or more symptoms associated with any of these conditions.
  • the use of the invention agents and methods can be combined with one or more conventional treatments for these disorders.
  • each R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 10 independently are -H, -OH, -
  • R 1 , R 2 , R 3 or R 4 together comprise an independent selected spiro ring, or
  • one or more of two adjacent R 1 -R 6 and R 10 comprise an independent!/ selected acetal, thioacetal, ketal or thioketal moiety, or
  • R 7 is -C(R 10 ) 2 -, -C(R 10 ) 2 -C(R 10 ) 2 -, -C(R 10 ) 2 -C(R 10 ) 2 -C(R 10 ) 2 -, -C(R 10 ) 2 -O-
  • R 8 and R 9 independentlyare -C(R 10 ) 2 -, -C(R 10 ) 2 -C(R 10 ) 2 -, -0-, -O-C(R 10 ) 2 -, -S-,
  • R 8 or R 9 independently are absent, leaving a 5-membered ring;
  • R 13 independentlyis C ⁇ alkyl
  • R PR independentlyis -H or a protecting group
  • D comprises two 5- or 6-membered rings, wherein the rings are fused or are linked by 1 or 2 bonds, or a metabolic precursor or a biologically active metabolite thereof.
  • 1 , 2, 3, 4 or more R 10 at the 1 , 4, 6, 8, 9, 12 and 14 positions are not hydrogen. In other embodiments, they are all hydrogen atoms.
  • the invention also provides for the use of a formula 1 compound to prepare a medicament for the treatment of a disease, condition or symptom that is caused by or associated with one or more of an autoimmune condition, an immune suppression condition, an infection, a cancer, a precancer, an inflammation condition, a neurological condition, a cardiovascular condition or a side-effect of radiation exposure or chemotherapy or a delayed adverse or unwanted effect of radiation exposure in a subject in need thereof.
  • the medicament is for administration to the subject or delivery to the subject's tissues beginning at least 1 day after the subject has been exposed to a dose of radiation that will cause or could potentially cause the one or more delayed adverse or unwanted effects of the radiation exposure or wherein the medicament is for administration to the subject or delivery to the subject's tissues beginning at least 1 day after the subject has been exposed to at least one subdose of a planned course of radiation exposures that will cause or could potentially cause the one or more delayed adverse effects or unwanted effects of the radiation exposure.
  • 1 , 2, 3, 4 or more R 10 at the 1 , 4, 6, 8, 9, 12 and 14 positions are not hydrogen. In other embodiments, they are all hydrogen atoms.
  • invention embodiments also provide a method to modulate an immune or cellular response in a subject in need thereof comprising administering to the subject, or delivering to the subject's tissues, an effective amount of a compound of formula 1
  • each R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 10 independently are -H, -OH, -OR PR , -SR PR ,
  • R 1 , R 2 , R 3 or R 4 together comprise an independently selected spiro ring, or
  • R 1 -R 6 and R 10 comprise an independently selected acetal, thioacetal, ketal or thioketal moiely, or [0045] all R 3 and R 4 together comprise a structure of formula 2
  • R 7 is -C(R 10 ) 2 -, -C(R 10 ) 2 -C(R 10 ) 2 -, -C(R 10 ) 2 -C(R 10 ) 2 -C(R 10 ) 2 -, -C(R 10 ) 2 -O-
  • R 8 and R 9 independentlyare -C(R 10 ) 2 -, -C(R 10 ) 2 -C(R 10 ) 2 - r -0-, -O-C(R 10 ) 2 -, -S-, -S-C(R 10 ) 2 -, -NR PR - or -NR PR -C(R 10 ) 2 -, or one or both of R 8 or R 9 independently are absent, leaving a 5-membered ring; [0049] R 13 independentlyis Cm alkyl;
  • R PR independentlyis -H or a protecting group
  • D comprises two 5- or 6-membered rings, wherein the rings are fused or are linked by 1 or 2 bonds, or a metabolic precursor or a biologically active metabolite thereof, optionally provided that if the subject is in need of enhanced hemopoiesis, the compound is not 5-androstene-3 ⁇ -ol-17-one, 5-androstene-3 ⁇ ,17 ⁇ -diol, 5-androstene-3 ⁇ ,7 ⁇ ,17 ⁇ -triol or a derivative of any of these three compounds that can convert to these compounds by hydrolysis.
  • Immune and cellular response modulation includes enhancing Th1 immune responses, reducing Th2 immune responses, reducing inflammation and enhancing hemopoiesis. These compounds are useful in treating the diseases, conditions and symptoms described herein.
  • Other embodiments include a method to enhance the expression of one or more cytokines or interleukins that facilitate Th1 or Tc1 immune responses in a subject or to reduce the expression of one or more cytokines or interleukins that facilitate Th2 or Tc2 immune response in a subject comprising administering to the subject an effective amount of of a formula 1 compound, whereby the subject's Th1 or Td immune response is enhanced otthe subject's undesired Th2 orTc2 immune response is reduced.
  • a further embodiment is a method to modulate a subject's innate immunity
  • Th1 immune responses, Tc1 immune responses, Th2 immune responses, Tc2 immune responses, or inflammation comprising administering an effective amount of a formula 1 compound to a subject or delivering the formula 1 compound to the subject's tissues.
  • An "invention formulation”, “formulation” or the like means a composition that one can administer to a subject, e.g., human or animal, without further manipulations that change the ingredients or the ingredient proportions that are present.
  • Formulations are suitable for human or veterinary applications and would typically have expected characteristics for the formulation, e.g., parenteral formulations for human use would usually be sterile.
  • compositions means a composition, that is a formulation or that can be an intermediate one can use to make the formulations, i.e., a change(s) in an ingredient(s) or its amount(s) may be needed to make a formulation.
  • Compositions may also comprise other types of materials, e.g., reagents for assays or cells that are optionally contacted with a formula 1 compound or mixtures of compounds.
  • invention compositions include compositions where further processing may be required before it is a formulation, e.g., mixing or addition of a desired amount of an ingredient.
  • phrases such as "administration of a compound of formula 1", “treatment with a formula 1 compound” or similar terms mean that the compound(s) is administered to, or delivered to, the subject or to the subject's tissues by one or more suitable methods, e.g., by an oral, topical, parenteral, buccal orsublingual route.
  • Expressions such as "a formula 1 compound(s)", "a formula 1 compound” and the like mean invention compositions or formulations where one or more than one formula 1 compound is present, e.g., in a composition, or is used in the disclosed method, typically 1 , 2, 3 or 4, usually 1. Any reference to a “formula 1 compound”, “one or more compounds of formula 1” or the like means that the formula 1 compound can have the formula 2 structure or any other structure disclosed herein that is within the definition of formula 1 compounds.
  • references to subject matter "as disclosed herein” such as a “therapeutic treatment or agent as disclosed herein", a “dosing protocol as disclosed herein” or a “clinical condition or symptom as disclosed herein” or the like means a treatment, agent, protocol, condition, symptom or the like that is described herein or in any reference that is cited herein.
  • An “excipien , “carrier”, “pharmaceutically acceptable carrier” or similar terms mean one or more components) or ingredient(s) that is acceptable in the sense of being compatible with the other ingredients of invention compositions or formulations and not overly deleterious to the patient, animal, tissues or cells to which the formulation is to be administered.
  • excipients include liquids, such as benzyl benzoate, cottonseed oil, N,N-dimethylacetamide, a C 2 . 12 alcohol (e.g., ethanol), glycerol, peanut oil, a polyethylene glycol ("PEG”), vitamin E, poppyseed oil, propylene glycol, safflower oil, sesame oil, soybean oil and vegetable oil. Any solid excipient may be a fine powder or granulated. Excipients, as used herein may optionally exclude one or more excipient, e.g., chloroform, dioxane, vegetable oil, DMSO, other excipients or any combination of these.
  • excipients include liquids, such as benzyl benzoate, cottonseed oil, N,N-dimethylacetamide, a C 2 . 12 alcohol (e.g., ethanol), glycerol, peanut oil, a polyethylene glycol (“PEG”), vitamin E, poppys
  • Excipients include one or more components typically used in the pharmaceutical formulation arts, e.g., one, two or more of fillers, binders, disintegrants, dispersants, preservatives, glidants and lubricants.
  • Exemplary excipients include povidone, crospovidone, corn starch, carboxymethyl cellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, gum arabic, polysorbate 80, butylparaben, propylparaben, methylparaben, BHA, EDTA, sodium lauryl sulfate, sodium chloride, potassium chloride, titanium dioxide, magnesium stearate, castor oil, olive oil, vegetable oil, buffering agents such as sodium hydroxide, monobasic sodium phosphate, dibasic sodium phosphate, potassium hydroxide, monobasic potassium phosphate, dibasic potassium phosphate, tribasic potassium phosphate, potassium carbonate, potassium bicarbonate, ammonium hydroxide, ammouium chloride, sac
  • a "subject” means a human or animal. Usually the animal is a mammal or vertebrate such as a primate, rodent, lagomorph, domestic animal or game animal. Primates include chimpanzees, cynomologous monkeys, spider monkeys, and macaques, e.g., Rhesus or Pan. Rodents and lagomorphs include mice, rats, woodchucks, ferrets, rabbits and hamsters.
  • Domestic and game animals include cows, horses, pigs, sheep, deer, bison, buffalo, mink, felines, e.g., domestic cat, canines, e.g., dog, wolf and fox, avian species, e.g., chicken, turkey, emu and ostrich, and fish, e.g., trout, catfish and salmon.
  • Subject includes any subset of the foregoing, e.g., all of the above, but excluding one or more groups or species such as humans, primates or rodents.
  • subsets of subjects include subjects of a given species or group of species of varying ages, e.g., young humans, e.g., about 1 week of age to about 9 years of age, adolescent humans, e.g., about 10-19 years of age, adult humans, e.g., about 20-100 years of age, and mature adult or elderly humans, e.g., at least about 55 years of age, at least about 60 years of age, at least about 65 years of age or a range of ages such as about 60-100 years of age.
  • prevention or treatment of a disease, condition or symptom may include or exclude any subset of subjects that are grouped by age.
  • an effective amount means an amount of a formula 1 compound that is sufficient to elicit a desired response, e.g., restoration of normal immune responsiveness in an immunodeficient subject to which it is administered or to detectable modulation or amelioration of an immune or cellular parameter or a clinical condition or symptom.
  • An effective amount may be a a single dose or two or more subdoses of a forlula 1 compound administered in one day, or it may be administered as multiple doses over a period of time, e.g., over 2 days to about 1 year.
  • References such as “a disease”, “a disorder”, “a condition”, “a symptom' or "a complication” or the like mean that one or more disease, disorder, condition, symptom or complication may be treated.
  • Terms such as “use”, “treat”, “treatment”, “address” or the like in the context of using the formula 1 compounds in the treatment methods or other methods disclosed herein mean that a formula 1 compound is administered to a subject, delivered to the subject's tissues or contacted with tissues, cells or cell free systems, e.g., as described herein or a reference cited herein. Typically such use or treatment results in detectable improvement in or amelioration of the condition or symptom being treated.
  • Such amelioration may be transient, e.g., lasting for at least a few, e.g., about 1 to 24, hours or days, e.g., about 1-,7 days, or amelioration may be prolonged, e.g., lasting about 8 to about 60 days or more, or it may be permanent.
  • a treatment may slow the progression or severity of a disease or symptom.
  • a use or treatment may result in detectable modulation in a relevant immune parameter such as modulation of the level or activity of a target effector or suppressor immune cell population, interleukin, cytokine, chemokine, immunoglobulin or modulation of the level or activity of a relevant transcription factor, enzyme or cell biological activity.
  • a treatment with the compounds may be used to prevent the onset of a disease, symptom or complication or to ameliorate a preexisting disease, condition, symptom or complication, or to facilitate elimination of a disease, condition, symptom or complication.
  • “Ameliorate”, “amelioration”, “improvement” or the like means a detectable improvement or a detectable change consistent with improvement occurs in a subject or in at least a minority of subjects, e.g., in at least about 2%, 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 100% or in a range about between any two of these values.
  • Such improvement or change may be observed in treated subjects as compared to subjects not treated with a formula 1 compound, where the untreated subjects have, or are subject to developing, the same or similar disease, condition, symptom or the like.
  • Amelioration of a disease, condition, symptom or assay parameter may be determined subjectively or objectively, e.g., self assessment by a subject(s), by a clinician's assessment or by conducting an appropriate assay or measurement, including, e.g., a quality of life assessment, a slowed progression of a disease(s) or condition(s), a reduced severity of a disease(s) or condition(s), or a suitable assay(s) for the level or activity(ies) of a biomolecule(s), cell(s) or by detection of cell migration within a subject.
  • Amelioration may be transient, prolonged or permanent or it may be variable at relevant times during or after a formula 1 compound is administered to a subject or is used in an assay or other method described herein or a cited reference, e.g., within about 1 hour of the administration or use of a formula 1 compound to about 3, 6, 9 months or more after a subject(s) has received a formula 1 compound.
  • the "modulation" of, e.g., a symptom, level or biological activity of a molecule, replication of a pathogen, cellular response, cellular activity or the like, means that the cell, level or activity, or the like is detectably increased or decreased.
  • Such increase or decrease may be observed in treated subjects as compared to subjects not treated with a formula 1 compound, where the untreated subjects have, or are subject to developing, the same or similar disease, condition, symptom or the like.
  • Such increases or decreases may be at least about 2%, 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 100%, 150%, 200%, 250%, 300%, 400%, 500% or more or about within any range about between any two of these values.
  • Modulation may be determined subjectively or objectively, e.g., by the subject's self assessment, by a clinician's assessment or by conducting an appropriate assay or measurement, including, e.g., quality of life assessments or suitable assays for the level or activity of molecules, cells or cell migration within a subject. Modulation may be transient, prolonged or permanent or it may be variable at relevant times during or after a formula 1 compound is administered to a subject or is used in an assay or other method described herein or a cited reference, e.g., within about 1 hour of the administration or use of a formula 1 compound to about 3, 6, 9 months or more after a subject(s) has received a formula 1 compound.
  • phrases such as "antigen”, "immunogen” or the like mean a molecule that comprises one or more epitopes that are capable of stimulating a subject's immune system to make, e.g., a secretory, humoral or cellular antigen-specific response against the antigen or immunogen. These terms also include fragments or synthetic or natural derivatives of these molecules that retain at least a detectable capacity, e.g., at least about 10%, 20%, 30%, 40%, 50% or more of the native antigen's antigenic capacity, to stimulate a subject's immune system in a desired manner.
  • Vaccine composition means an agent suitable for stimulating a subject's immune system to ameliorate a current condition or to protect against or to reduce present or future harm or infection, e.g., reduced tumor cell proliferation or survival, reduced pathogen repl ation or spread in a subject or a detectably reduced unwanted symptom(s) associated with a condition.
  • Vaccines may modulate, typically detectably enhance, humoral, cell mediated or innate immune responses.
  • Immunization means the process of inducing a detectable and continuing moderate or high level of antibody or cellular immune response that is directed against an antigen to which the subject has been exposed. Such responses are typically detectably maintained for at least about 3-48 months or more.
  • compositions, formulations, or methods that comprise one or more specified components, elements or steps.
  • invention embodiments also specifically include those compounds, compositions, formulations or methods that consist of or that consist essentially of those specified components, elements or steps.
  • the terms “comprising”, “consist of and “consist essentially of " have meanings as follows. Compositions or methods that "comprise” a component or step are open and they optionally include on those specified compositions or methods plus an additional component(s) or step(s).
  • compositions or methods that "consist of a component or step would not include on those compositions or methods having appreciable amounts of an additional components) or an additional step(s).
  • Compositions or methods that "consist essentially of a component or step would optionally include on those compositions or methods having minor amounts of an additional components) or an additional step(s), but without significantly affecting the salient desired properties of the specified composition.
  • Alkyl as used here means linked normal, secondary, tertiary or cyclic carbon atoms, i.e., linear, branched, cyclic or any combination thereof.
  • Alkyl moieties may be saturated, or unsaturated, i.e., the moiety may comprise one or more independently selected double bonds or triple bonds.
  • Unsaturated alkyl moieties include moieties as described for alkenyl and alkynyl moieties described below.
  • the number of carbon atoms in an alkyl group or moiety is 1 to about 50, e.g., about 1-30 or about 1-20, unless otherwise specified, e.g., C, ⁇ alkyl means an alkyl moiety containing 1 , 2, 3, 4, 5, 6, 7 or 8 carbon atoms.
  • species may include methyl, ethyl, 1- propyl (n-propyl), 2-propyl (/-propyl, -CH(CH 3 ) 2 ), 1 -butyl (n-butyl), 2-methyl-1 -propyl (/ ' -butyl, - CH 2 CH(CH 3 ) 2 ), 2-butyl (s-butyl, -CH(CH 3 )CH 2 CH 3 ), 2-methyl-2-propyl (f-butyl, -C(CH 3 ) 3 ), 1 - pentyl (n-pentyi), 2-pentyl (-CH(CH 3 )CH 2 CH 2 CH 3 ), 3-pentyl (-CH(CH 2 CH 3 ) 2 ), 2-methyl-2-butyl (-C(CH 3 ) 2 CH 2 CH 3 ), 3-methyl-2-butyl (-CH(CH 3 )CH(CH 3 ) 2 ), 3-methyl-1 -butyl (-CH(CH 3
  • the number of carbon atoms in an alkenyl group or moiety is 2 to about 50, e.g., about 2-30 or about2-20, unless otherwise specified, e.g., C 2 . 8 alkenyl or C2- 8 alkenyl means an alkenyl moiety containing 2, 3, 4, 5, 6, 7 or 8 carbon atoms.
  • Alkynyl as used here means a moiety that comprises linked normal, secondary, tertiary or cyclic carbon atoms, i.e., linear, branched, cyclic or any combination thereof, that comprises one or more triple bonds (-C ⁇ C-), e.g., 1, 2, 3, 4, 5, 6 or more, typically 1 or 2 triple bonds, optionally comprising 1 , 2, 3, 4, 5, 6 or more double bonds, with the remaining bonds being single bonds.
  • the number of carbon atoms in an alkenyl group or moiety is 2 to about 50, e.g., about 2-30 or about2-20, unless otherwise specified, e.g., C 2 .
  • a alkynyl or C2-8 alkynyl means an alkynyl moiety containing 2, 3, 4, 5, 6, 7 or 8 carbon atoms.
  • groups and species may include -CCH, -CCCH , -GCCH 2 CH 3 , -CCC 3 H 7 , -CCCH 2 C 3 H 7 , -(CH 2 ) n -(C ⁇ C)-(CH 2 ) m -CH 3 , and (CH 2 ) m -CH 2 C ⁇ CH, where n and m independent are 0, 1 , 2, 3, 4, 5, 6, 7 or 8.
  • "Aryl” means phenyl or naphthyl.
  • Substituted alkyl "substituted alkenyl", "substituted heterocycle"
  • substituted aryl means an alkyl, alkenyl, heterocycle, aryl, monosaccharide or other group or moiety as defined herein that has a substituent(s) or that comprises a substituent(s) that replaces a hydrogen atom(s) and is bonded to a carbon atom(s) or a substituent(s) that interrupts a carbon atom chain.
  • Substituted heterocycles may have a substituent bonded to a ring carbon or a ring heteroatom such as a nitrogen.
  • Substituents are independently chosen when more than one is present.
  • Alkenyl and alkynyl groups that comprise a substituent(s) are optionally substituted at a carbon that is one or more methylene moiety removed from the double bond, e.g., separated by one, two, three or more independently selected -CH 2 -, -CH(C 1 . 6 optionally substituted alkyl)-, -CH(C 1 . 6 optionally substituted alkenyl)-, -CH(C 1 .
  • Heterocycle or “heterocyclic” includes by way of example and not limitation the heterocycles described in Paquette, Leo A.; "Principles of Modem Heterocyclic
  • Heterocycles are typically bonded to moieties of which they are a part through a ring carbon atom, a ring nitrogen atom or a ring sulfur atom.
  • heterocycles include by way of example and not limitation pyridyl, thiazolyl, tetrahydrothiophenyi, sulfur oxidized tetrahydrothiophenyi, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, thianaphthalenyl, indolyl, indolenyl, quinolinyl, isoquinolinyl, benzimidazolyl, piperidinyi, 4-piperidonyi, pyrrolidinyl, 2-pyrrolidonyl, pyrrolinyl, tetrahydrofuranyl, tetrahydroquinolinyi, tetrahydroisoquinolinyl, decahydroquinolinyi, octahydroisoquinolinyi, azocinyl,
  • carbon bonded heterocycles are bonded at position 2, 3, 4, 5, or 6 of a pyridine, position 3, 4, 5, or 6 of a pyridazine, position 2, 4, 5, or 6 of a pyrimidine, position 2, 3, 5, or 6 of a pyrazine, position 2, 3, 4, or 5 of a furan, tetrahydrofuran, thiofuran, thiophene, pyrrole ortetrahydropyrrole, position 2, 4, or 5 of an oxazole, imidazole or thiazole, position 3, 4, or 5 of an isoxazole, pyrazole, or isothiazole, position 2 or 3 of an aziridine, position 2, 3, or 4 of an azetidine, position 2, 3, 4, 5, 6, 7, or 8 of a quinoline or position 1 , 3, 4, 5, 6, 7, or 8 of an isoquinoline.
  • carbon bonded heterocycles include 2-pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl, 6-pyridyl, 3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl, 6-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5— pyrimidinyl, 6- pyrimidinyl, 2-pyrazinyl, 3-pyrazinyl, 5-pyrazinyl, 6-pyrazinyl, 2-thiazolyl, 4-thiazolyl, or 5- thiazolyl.
  • nitrogen bonded heterocycles are bonded at position 1 of an aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline, 3-pyrroline, imidazole, imidazolidine, 2-imidazoline, 3-imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3- pyrazoline, piperidine, piperazine, indole, indoline, 1 H-indazole, position 2 of a isoindole, or isoindoline, position 4 of a morpholine, and position 9 of a carbazole, or ⁇ -carboline.
  • nitrogen bonded heterocycles include 1-aziridyl, 1-azetedyl, 1-pyrrolyl, 1- imidazolyl, 1-pyrazolyl, and 1-piperidinyi.
  • Heteroaryl means an aromatic ring or two or more fused rings that contain one or more aromatic rings where the ring or fused rings comprise 1 , 2, 3 or more heteroatoms, usually oxygen (-0-), nitrogen (-NX-) or sulfur (-S-) where X is -H, a protecting group or C, ⁇ alkyl, usually -H. Examples are as described for heterocycle.
  • Alcohol as used herein means an alcohol that comprises a d. 12 alkyl moiety substituted at a hydrogen atom with one hydroxyl group.
  • Alcohols include methanol, ethanol, n-propanol, /-propanol, n-butanol, / ' -butanol, s-butanol, f-butanol, n-pentanol, /-pentanol, n- hexanol, cyclohexanol, n-heptanol, n-octanol, n-nonanol and n-decanol.
  • the carbon atoms in alcohols can be straight, branched or cyclic.
  • Alcohol includes any subset of the foregoing, e.g., C 2 - 4 alcohols (alcohols having 2, 3 or 4 carbon atoms).
  • "Halogen” means fluorine, chlorine, bromine or iodine.
  • Protecting group means a moiety that prevents the atom to which it is linked from participating in unwanted reactions.
  • R PR may be hydrogen or a protecting group for the oxygen atom found in a hydroxyl
  • R PR may be hydrogen or a carboxyl protecting group
  • R PR may be hydrogen or a protecting group for sulfur in thiols for instance
  • R PR may be hydrogen or a nitrogen atom protecting group for primary or secondary amines. Hydroxyl, amine and other reactive groups are found in formula 1 compounds at, e.g., R 1 or R 2 .
  • Ester means a moiety that comprises a -C(0)-0- structure.
  • esters as used here comprise an organic moiety containing about 1 -50 carbon atoms (e.g., about 2- 20 carbon atoms) and 0 to about 10 independent ⁇ selected heteroatoms (e.g., O, S, N, P, Si), where the organic moiety is bonded to a formula 1 steroid nucleus at, e.g., R 1 or R 2 through the -C(0)-0- structure, e.g., organic moiety-C(0)-0-steroid or organic moiety-O- C(0)-steroid.
  • the organic moiety usually comprises one or more of any of the organic groups described above, e.g., C 1 . 2 0 alkyl moieties, C 2 . 20 alkenyl moieties, C 2 .
  • the organic moiety includes compounds defined by the R 4 variable.
  • the organic moieties exclude obviously unstable moieties, e.g., -0-0-, except where such unstable moieties are transient species that one can use to make a compound with sufficient chemical stability for one or more of the uses described herein, including for synthesis of the formula 1 or other compounds.
  • substitutions listed above are typically substituents that one can use to replace one or more carbon atoms, e.g., -O- or -C(O)-, or one or more hydrogen atom, e.g., halogen, -NH 2 or - OH.
  • Exemplary esters include one or more independently selected acetate, enanthate, propionate, isopropionate, cyclopropionate, isobutyrate, butyrate, valerate, caproate, isocaproate, hexanoate, heptanoate, octanoate, nonanoate, decanoate, undecanoate, phenylacetate or benzoate, which are typically hydroxyl esters.
  • Thioester means a moiety that comprises a -C(0)-S- structure.
  • thioesters as used here comprise an organic moiety containing about 1-50 carbon atoms (e.g., about 2-20 carbon atoms) and 0 to about 10 heteroatoms (e.g., O, S, N, P, Si), where the organic moiety is bonded to a formula 1 steroid nucleus at a variable group such as R 1 , R 2 , R 3 , R 4 or R 10 through the -C(S)-0- structure, e.g., organic moiety-C(S)-0-steroid or organic moiety-0-C(S)-steroid.
  • the organic moiety is as described above for esters.
  • Thionoester means a moiety that comprises a -C(S)-0- structure.
  • thionoesters as used here comprise an organic moiety containing about 1-50 carbon atoms (e.g., about 2-20 carbon atoms) and 0 to about 10 heteroatoms (e.g., O, S, N, P, Si), where the organic moiety is bonded to a formula 1 steroid nucleus at a variable group such as R 1 , R 2 , R 3 , R 4 or R 10 through the -C(S)-0- structure, e.g., organic moiety-C(S)-0-steroid or organic moiety-0-C(S)-steroid.
  • the organic moiety is as described above for esters.
  • “Acetal” means a moiety that comprises (1 ) a -0-[C(CR 36 ) 2 ] ⁇ . 4 -0- structure where the open valences are bonded to adjacent carbons on the steroid nucleus, e.g., the 16 and 17 positions or the 2 and 3 positions, or (2) a -0-[C(CR 36 ) 2 ] ⁇ .
  • each R 36 independentlyis -H, -F, -Cl, -Br, -I or an organic moiety such as C1-6 alkyl (e.g., methyl or ethyl), C2-6 alkenyl, aryl or a heterocycle, any of which are optionally substituted, e.g., -CF 3 or -CH 2 OH.
  • acetals as used here comprise an organic moiety containing about 1- 50 carbon atoms (e.g., about 2-20 carbon atoms) and 0 to about 10 heteroatoms (e.g., O, S, N, P, Si), where the organic moiety is bonded to a formula 1 steroid nucleus at variable groups such as R , R 2 , R 3 , R 4 or R 10 through the -0-[C(CR 36 ) 2 ].
  • Ketal and thioketal mean an organic moiety that is bonded to two adjacent steroid ring atoms in the formula 1 compounds, e.g., ring atoms at the 1-2, 2-3, 3-4, 6-7, 14- 15, 15-16 or 16-17 positions.
  • the steroid ring atoms are carbon and the ketal is bonded to each adjacent carbon by an oxygen atom.
  • Thioketals are bonded through one oxygen and one sulfur atom.
  • One, two or more of two adjacent R 1 -R 6 and R 10 may comprise an independently selected ketal or thioketal in any of the formula 1 compounds disclosed herein.
  • the oxygen or sulfur atoms in ketals and thioketals are linked by an optionally substituted alkyl moiety.
  • the alkyl moiety is an optionally substituted C1-C6 alkylene such as -C(CH 3 ) 2 -, -CH(CH 3 )-, -CH 2 -, -CH 2 -CH 2 -, -C(C2-C4 alkyl) 2 - or -CH(C2-C4 alkyl)-.
  • Exemplary ketal and thioketals include -0-C(CH 3 ) 2 -0-, -0-C(CH 3 )(heterocycle)-0-, - 0-CH(heterocycle)-0-, -0-C(CH 3 )(aryl)-0-, -0-CH(aryl)-0-, -S-C(CH 3 ) 2 -0-, -0-CH 2 -CH 2 -0-, - 0-C(CH 3 ) 2 -CH 2 -0-, -0-C(CH 3 ) 2 -C(CH 3 ) 2 -0-, -S-C(CH 3 ) 2 -CH 2 -0-, -0-C(CH 3 ) 2 -CH 2 -S- and the like.
  • Thioacetal means a moiety that comprises (1 ) a -S-[C(CR 36 ) 2 ] ⁇ - -0- or -S-
  • each R 36 independently is -H, -F, -Cl, -Br, -I or an organic moiety such as C1-6 alkyl (e.g., methyl or ethyl), C2-6 alkenyl, aryl or a heterocycle, any of which are optionally substituted, e.g., -CF 3 or -CH 2 OH.
  • thioacetals as used here comprise an organic moiety containing about 1-50 carbon atoms (e.g., about 2-20 carbon atoms) and 0 to about 10 heteroatoms (e.g., O, S, N, P, Si), where the organic moiety is bonded to a formula 1 steroid nucleus at variable groups such as R 1 , R 2 , R 3 , R 4 or R 10 through the -S-[C(CR 36 ) 2 ] M -0- or -S-[C(CR 36 ) 2 ] M -S- structure, e.g., 16-steroid-S-[C(CR 36 ) 2 ] ⁇ - 4 -0-17-steroid, 16-steroid-0-[C(CR 36 ) 2 ] -S-17-steroid, 16-steroid-S-[C(CR 3B ) 2 ] 1 .
  • R 1 , R 2 , R 3 , R 4 or R 10 through the -S-[C(CR 36
  • Phosphoester or "phosphate ester” means a moiety that comprises a -O-
  • phosphoesters as used here comprise a hydrogen atom, a protecting group or an organic moiety containing about 1-50 carbon atoms and 0 to about 10 heteroatoms (e.g., O, S, N, P, Si) linked to a formula 1 steroid nucleus at a variable group such as R 1 -R 6 , R 10 , R 15 , R 17 or R 18 through the -0-P(0)(0)-0- structure, e.g., organic moiety-0-P(0)(OH)-0-steroid.
  • the organic moiety is as described above foresters.
  • Phosphothioester means a moiety that comprises a -0-P(SR PR )(0)-0- structure where R PR is -H, a protecting group or an organic moiety as described for esters.
  • phosphothioesters as used here comprise a hydrogen atom, a protecting group or an organic moiety containing about 1-50 carbon atoms and 0 to about 10 heteroatoms (e.g., O, S, N, P, Si) linked to a formula 1 steroid nucleus at a variable group such as R 1 -R 6 , R 10 , R 15 , R 17 or R 18 through the -0-P(0)(0)-0- structure, e.g., organic moiety-0-P(0)(SH)-0- steroid.
  • Phosphonoester means a moiety that comprises a -P(OR PR )(0)- structure where R PR is -H, a protecting group oran organic moiety as described for esters.
  • phosphonoesters as used here comprise a hydrogen atom, a protecting group or an organic moiety containing about 1-50 carbon atoms and 0 to about 10 heteroatoms (e.g., O, S, N, P, Si) linked to a formula 1 steroid nucleus at a variable group such as R 1 -R 6 , R 10 , R 15 , R 17 or R 18 through the -P(OR PR )(0)-0- structure, i.e., organic moiety-P(OR PR )(0)-0-steroid or steroid-P(OR PR )(0)-0-organic moiety.
  • the organic moiety is as described above for esters.
  • Phosphiniester means a moiety that comprises a -P(0)H- structure where
  • R PR is -H, a protecting group oran organic moiety as described for esters.
  • phosphiniesters as used here comprise a hydrogen atom, a protecting group oran organic moiety containing about 1-50 carbon atoms and 0 to about 10 heteroatoms (e.g., O, S, N, P, Si) linked to a formula 1 steroid nucleus at a variable group such as R 1 -R 6 , R 10 , R 15 , R 17 or R 18 through the -P(0)H- structure, i.e., organic moiety-P(0)H-steroid or steroid-P(0)H- organic moiety.
  • the organic moiety is as described above for esters.
  • Sulfate ester means a moiety that comprises a -0-S(0)(0)-0- structure.
  • sulfate esters as used here comprise a hydrogen atom, a protecting group oran organic moiety containing about 1-50 carbon atoms and 0 to about 10 heteroatoms (e.g., O, S, N, P, Si) linked to a formula 1 steroid nucleus at a variable group such as R 1 -R 6 , R 10 , R 15 , R 17 or R 18 through the -0-S(0)(0)-0- structure, e.g., organic moiety-0-S(0)(0)-0-steroid.
  • the organic moiety is as described above for esters.
  • Sulfite ester means a moiety that comprises a -0-S(0)-0- structure.
  • sulfite esters as used here comprise an organic moiety containing about 1-50 carbon atoms and 0 to about 10 heteroatoms (e.g., O, S, N, P, Si) linked to a formula 1 steroid nucleus at a variable group such as R 1 -R 6 , R 10 , R 15 , R 17 or R 18 through the -O-S(O)- O- structure, e.g., organic moiety-0-S(0)-0-steroid.
  • the organic moiety is as described above for esters.
  • Amide means an organic moiety as described for ester that comprises 1 , 2,
  • the -C(0)NR PR - group is linked to the steroid nucleus at a variable group such as R 1 -R 6 , R 10 , R 15 , R 17 or R 18 , i.e., organic moiety-C(0)NR PR -steroid or steroid-C(0)NR PR -organic moiety.
  • the organic moiety is as described above for esters. [00103] "Ether” means an organic moiety as described for ester that comprises 1 , 2,
  • the -O- group is linked to the steroid nucleus at a variable group such as R 1 -R 6 , R 10 , R 15 , R 17 or R 18 , e.g., organic moiety-O-steroid.
  • the organic moiety is as described above for esters.
  • "Thioether” means an organic moiety as described for ester that comprises 1 , 2, 3, 4 or more -S- moieties, usually 1 or 2.
  • the -S- group is linked to the steroid nucleus at a variable group such as R 1 -R 8 , R 10 , R 15 , R 17 or R S , e.g., organic moiety-S-steroid.
  • the organic moiety is as described above for esters.
  • “Acyl group” means an organic moiety as described for ester that comprises
  • the -C(O)- group is linked to the steroid nucleus at a variable group such as R 1 -R 6 , R 10 , R 15 , R 17 or R 18 , e.g., organic moiety-
  • C(0)-steroid The organic moiety is as described above for esters.
  • Thioacyl means an organic moiety as described for ester that comprises 1 ,
  • the -C(S)- group is linked to the steroid nucleus at a variable group such as R 1 -R 6 , R 10 , R 15 , R 17 or R 18 , e.g., organic moiety-C(S)- steroid.
  • the organic moiety is as described above for esters.
  • Carbonate means an organic moiety as described for ester that comprises
  • carbonate groups as used here comprise an organic moiety containing about 1 -50 carbon atoms and 0 to about 10 heteroatoms (e.g., O, S, N, P, Si) linked to a formula 1 steroid nucleus at a variable group such as R 1 -R 6 , R 10 , R 15 , R 17 or R 18 through the -0-C(0)-0- structure, e.g., organic moiety-0-C(0)-0-steroid.
  • the organic moiety is as described above for esters.
  • “Carbamate” means an organic moiety as described for ester that comprises
  • carbamate groups as used here comprise an organic moiety containing about 1-50 carbon atoms and 0 to about 10 heteroatoms (e.g., O, S, N, P, Si) linked to a formula 1 steroid nucleus at a variable group such as R 1 -R 6 , R 10 , R 15 , R 17 or R 18 through the -0-C(0)-NR PR - structure, e.g., organic moiety-0-C(0)-NR PR -steroid or steroid-0-C(0)-NR PR -organic moiety.
  • monosaccharide means a polyhydroxy aldehyde or ketone having the empirical formula (CH2 ⁇ )n where n is 3, 4, 5, 6 or 7.
  • Monosaccharide includes open chain and closed chain forms, but will usually be closed chain forms.
  • Monosaccharide includes hexofuranose and pentofuranose sugars such as 2'-deoxyribose, ribose, arabinose, xylose, their 2'-deoxyand 3'-deoxy derivatives and their 2', 3'-dideoxy derivatives.
  • Monosaccharide also includes the 2', 3' dideoxydidehydro derivative of ribose.
  • Monosaccharides include the D-, L- and DL-isomers of glucose, fructose, mannose, idose, galactose, allose, gulose, altrose, talose, fucose, erythrose, threose, lyxose, erythrulose, ribulose, xylulose, ribose, arabinose, xylose, psicose, sorbose, tagatose, glyceraldehyde, dihydroxyacetone and their monodeoxy or other derivatives such as rhamnose and glucuronic acid or a salt of glucuronic acid.
  • Monosaccharides are optionally protected or partially protected.
  • Exemplary monosacharides include
  • R 37 independentlyis hydrogen, a protecting group, acetamido (-NH-
  • R 38 is hydrogen, hydroxyl, -NH 2 , -NHR PR , optionally substituted alkyl such as methyl or ethyl, or a cation such as NH 4 + , Na + or K + and R 39 is hydrogen, hydroxyl, acetate, proprionate, optionally substituted alkyl such as methyl, ethyl, methoxy or ethoxy.
  • Optionally substituted alkyl group, optionally substituted alkenyl group, optionally substituted alkynyl group, optionally substituted aryl moiety and optionally substituted heterocycle mean an alkyl, alkenyl, alkynyl, aryl or heterocycle moiety that contains an optional substitution(s).
  • Such moieties include include C ⁇ . 2 o alkyl moieties, C 2 . 20 alkenyl moieties, C 2 . 20 alkynyl moieties, aryl moieties, C 2 . 9 heterocycles or substituted derivatives of any of these.
  • Optionally substituted "monosaccharide” comprise any C3-C7 sugar, D-, L- or
  • DL-configurations e.g., erythrose, glycerol, ribose, deoxyribose, arabinose, glucose, mannose, galactose, fucose, mannose, glucosamine, N-acetylneuraminic acid, N- acetylglucosamine, N-acetylgalactosamine that is optionally substituted at one or more hydroxyl groups.
  • Suitable substitutions are as described above for substituted alkyl moieties and include independently selected hydrogen, hydroxyl, protected hydroxyl, carboxyl, azido, cyano, -0-Ci.e alkyl, -S-C ⁇ e alkyl, -0-C 2 .
  • Optionally substituted "oligosaccharide" comprises two, three, four or more of any C3-C7 sugars that are covalently linked to each other.
  • the linked sugars may have D-, L- or DL-configurations. Suitable sugars and substitutions are as described for monosaccharides.
  • Nucleoside includes 3TC, AZT, D4T, ddl, ddC, G, A, U, C, T, dG, dA, dT and dC.
  • Polymer includes biocompatible organic polymers, e.g., PEGs and polyhydroxyalkyl polymers.
  • PEG means an ethylene glycol polymer that contains about 20 to about 2000000 linked monomers, typically about 50-1000 linked monomers, usually about 100- 300.
  • Polyethylene glycols include PEGs containing various numbers of linked monomers or having differing average molecular weights, e.g., PEG20, PEG30, PEG40, PEG60, PEG80, PEG100, PEG115, PEG200, PEG300, PEG400, PEG500, PEG600, PEG1000, PEG1500, PEG2000, PEG 3350, PEG4000, PEG4600, PEG5000, PEG6000, PEG8000, PEG11000, PEG12000, PEG2000000 and any mixtures thereof. [00117] As used herein, position numbers that are given for the formula 1 compounds use the numbering convention for cholesterol.
  • Spiro ring or "spiro structure” and similar terms mean cyclic structures that comprise 4, 5, 6, 7 or 8 ring members, i.e., they are 4-, 5-, 6-, 7- or 8-sided. In some embodiments, spiro structures share a carbon atom that is present in the steroid ring system, e.g., at the 1 , 2, 3, 4, 6, 7, 11 , 15, 16 or 17 positions of the formula 1 compounds. Spiro structures include lactone rings or cyclic esters. Such spirolactones include 5 and 6 membered rings, e.g., a spiro compound with a spiro ring atthe 17 position such as
  • X is -C(R 10 ) 2 - or -CHR 10 - and wherein independently selected R j1 1 0 groups are bonded to the 1-, 4-, 5-, 6-, 8-, 9-, 12-, and 14-positions.
  • the R 10 variable group independently is -H, -OH, -OCH 3 , -CH 3 or an optionally substituted alkyl.
  • 20% propylene glycol means 20% v/v propyiene glycol is present in an invention composition or formulation.
  • the amount of excipient indicated in inventbn compositions is not affected by the form used, e.g., NF or USP grade solvent or excipient
  • an invention composition that comprises about 30% polyethylene glycol 300 NF can instead comprise a USP counterpart, provided that other limitations, such as the amount of water present, are not exceeded.
  • innate immunity refers to one or more components typically associated with nonspecific immune defense mechanisms in a subject. These components include the alternate complement pathway, e.g., Factor B, Factor D and properdin; NK cells, phagocytes (monocytes, macrophages), neutrophils, eosinophils, dendritic cells, fibrocytes; anti-microbial chemicals, e.g., one or more of defensins; physical barriers - skin, mucosal epithelium; or certain interleukins, chemokines, cytokines, lung or alveolar macrophage respiratory burst activity or a lung surfactant protein such as surfactant protein A or surfactant protein D.
  • alternate complement pathway e.g., Factor B, Factor D and properdin
  • NK cells e.g., NK cells, phagocytes (monocytes, macrophages), neutrophils, eosinophils, dendritic cells, fibrocytes
  • Innate immunity plays a role in resistance to intracellular parasite infections, e.g., white blood cell infection, a liver infection, and other infections, e.g., lymph node infections.
  • Detectable enhancement of innate immunity mechanism by formula 1 compounds or method described herein can also enhance phagolysosome fusion or movement, which some pathogens, e.g., intracellular bacteria such as mycobacteria, or Listeria inhibit.
  • unwanted immune response and the like mean that a subject has or is subject to developing an immune response that is not desirable or is suboptimal for the subject's condition.
  • Such disregulation or unwanted responses can arise from various clinical conditions or diseases or as a result of treatment of such conditions or diseases, e.g., inflammation, autoimmunity, organ or tissue transplant rejection (e.g., allograft, xenograft), infections, cancers, chemotherapy treatments, trauma, allergy conditions or in conditions where a subject mounts a Th1 , Tc1 , Th2 or Tc2 immune response that is considered to be pathogenic, ineffective, insufficient or suboptimal.
  • Immune disregulation conditions are as described herein or in the cited references.
  • biological activity and the like mean a response or activity that is detectably modulated in response to the presence of a formula 1 compound.
  • Such responses or activities can be direct effects or indirect effects on one or more cellular activities or on the expression or level of one or more molecules that the affected cell(s) bind, sequester, synthesize or respond to.
  • Such responses or activities include a detectable change in the synthesis or level of one or more cytokines, growth factors, transcription factors (including receptors and their cofactors), enzymes, Th1- orTh2-associated antibody subtype responses or the like.
  • the cytokines, growth factors, transcription factors, enzymes or antibodies that are modulated are involved in the amelioration of a pathological condition or in the establishment, maintenance or progression of a pathological condition.
  • references to CD molecules, specific immune cell subsets, immune responses and the like generally use nomenclature that applies to molecules, cells or the like that are found in humans. Analogs or counterparts of such molecules, cells or the like in other species may have a differing nomenclature, but are included in this invention. A description of the nomenclature and function of various CD molecules and immune cell subsets are as found in the scientific literature. References to ThO, Th1 orTh2 cells and references to Th1 or Th2 immune responses in the context of human patients refers to the human counterparts of the murine ThO, Th1 or Th2 immune cells or responses. For reviews see, e.g., A.K.
  • Immunosuppressive molecule means molecules such as cyclosporin, cyclohexamide, mitomycin C, adriamycin, taxol and amphotericin B. These molecules tend to have toxicities toward the immune system and are directly or indirectly immunosuppressive, e.g., they are toxic to dividing cells, they inhibit proliferation of immune cell precursors or they can downregulate an otherwise desired or improved immune response or condition.
  • Step receptor means a gene product, typically a protein monomer or dimer that can bind to a ligand, e.g., a natural steroid, a steroid analog, or another ligand such as a formula 1 compound or a metabolic precursor thereof or a metabolite thereof, a lipid, e.g., a prostaglandin, or the like.
  • a ligand e.g., a natural steroid, a steroid analog, or another ligand such as a formula 1 compound or a metabolic precursor thereof or a metabolite thereof, a lipid, e.g., a prostaglandin, or the like.
  • Steroid receptors include orphan steroid receptors.
  • Orphan steroid receptors are proteins for which the natural ligand or biological function is at least partially unknown.
  • steroid receptors include homodimers, e.g., SXR and (CAR ⁇ ) 2 , and heterodimers, e.g., PXR-CAR ⁇ or RXR-CAR ⁇ .
  • Steroid receptors also include isoforms, e.g., PXR.1 and PXR.2 for the PXR receptor, and homologs of the steroid receptors, e.g., the homolog of CAR ⁇ known as MB67.
  • Isoforms are typically generated by different splicing pathways for a nuclear RNA from one gene, while homologs are typically a distinct copy of a steroid receptor gene, where the gene copy encodes only relatively small differences compared to the reference steroid receptor gene product. Such differences are most often found in areas other than the dimerization region and the steroid binding region of the steroid receptor's structure. Typically isoforms and homologs bind the same or similar ligands as the reference gene product or steroid receptor.
  • Steroid receptors may be of human or animal origin, e.g., obtained from cells, tissues or cDNA expression libraries derived from cells or tissues of any primate, rodent (including murine), avian, ovine, bovine, equine, canine or feline species or any of the species or any species within any group (e.g., Family or Genus) of species mentioned elsewhere herein or in any reference cited herein.
  • Modulation of steroid receptors by formula 1 compounds can arise from (1) their direct interaction with a steroid receptor or a cofactor thereof or (2) indirect effects such as (A) detectably increased or decreased synthesis or level of the steroiud receptor or (B) generation of a signal or stimulus that leads to detectable modulation of one or more biological activities of the receptor, e.g., detectable inhibition of steroid receptor mediated gene transcription or detectable enhancement of steroid receptor mediated gene transcription.
  • invention complexes or “complexes” include a complex that comprises a steroid receptor and a formula 1 compound and optionally other molecules.
  • these other molecules include (i) a DNA recognition sequence ("DNARS” hereafter), i.e., a sequence that the steroid receptor specifically recognizes and binds to and (ii) a transcription factor that can bind to the steroid receptor-formula 1 compound complex.
  • DNARS DNA recognition sequence
  • these complexes can arise in cells in vitro or in vivo, or in cell-free systems.
  • Complexes include, for example, steroid receptor heterodimer-formula 1 compound combinations, steroid receptor homodimer-formula 1 compound combinations, steroid receptor monomer- formula 1 compound combinations, steroid receptor heterodimer-formula 1 compound-DNA (or DNARS) combinations, steroid receptor homodimer-formula 1 compound-DNA (or DNARS) combinations, steroid receptor heterodimer-formula 1 compound-transcription factor combinations, steroid receptor homodimer-formula 1 compound-transcription factor combinations, steroid receptor heterodimer-formula 1 compound-DNA (or DNARS)- transcription factor combinations and steroid receptor homodimer-formula 1 compound-DNA (or DNARS)-transcription factor combinations.
  • An "agonist” or an “antagonist” is a compound or composition that respectively, either detectably increases or decreases the activity of a receptor, an enzyme or another biological molecule, which can lead to increased or decreased transcription of a regulated gene or to another measurable effect.
  • the increase or decrease in a receptor's or enzyme's activity will be an increase or a decrease of at least about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or a range about between any two of these values, for one or more measurable activities.
  • Receptors, their accessory factors and associated transcription factors can modulate transcription of their target gene(s) by detectably enhancing transcription or decreasing it.
  • Biological activities of receptors may also include modulating biological responses such as signal transduction within a cell or ion flux, e.g., sodium, potassium or calcium, across cell or organelle membranes.
  • compositions such as "biologically active metabolite” and the like mean derivatives of the formula 1 compounds that retain a detectable level, e.g., at least about 10%, at least about 20%, at least about 30% or at least about 50%, of at least one desired activity of the parent compound, e.g., antiinflammatory activity or stimulation of a desired immune response. Determination of a desired activity is accomplished essentially as described herein. Such metabolites can be generated in the gastrointestinal tract, in blood or in one or more subject tissues.
  • Such metabolites are detected using standard analytical methods, e.g., GC-MS analysis of an optionally radiolabeled formula 1 compound and its metabolites, in blood, urine or other biological samples after it is administered to a subject by one or more routes as disclosed herein.
  • Terms such as "metabolic precursor" of formula 1 compounds and the like can include compounds that generate a detectable level of the formula 1 compound or a detectable level, e.g., at least about 10%, at least about 20%, at least about 30% or at least about 50%, of at least one desired activity of the formula 1 compound. Determination of a desired activity is accomplished essentially as described herein. Conversion of metabolic precursors can occur in the gastrointestinal tract, in blood or in one or more subject tissues.
  • amino acid means an amino acid moiety that comprises any naturally- occurring or synthetic amino acid residue, i.e., any moiety comprising at least one carboxyl and at least one amino residue directly linked by one, two three or more carbon atoms, typically one ( ⁇ ) carbon atom.
  • the nature and identity of the intervening structure located between the carboxyl and amino groups can have a variety of structures including those described herein.
  • amino acids linked to the steroid through the amine group have sufficient conformation and length to be capable of autocatalytic hydrolysis of the amino acid-steroid bond and release of the steroid.
  • amino acids can comprise intervening ethylene, propylene, butylene, or pentylene groups or their substituted analogs, such as for example, oxyesters or ethers in which oxygen replaces carbon and, as appropriate, hydrogen.
  • intervening structure would be -CH-O- C(R 22 )(R 23 )-, where R 22 and R 23 are independent selected hydrogen or organic moieties as described above for esters.
  • one of R 22 and R 23 is hydrogen and the other is a C2-20 organic moiety.
  • the organic moieties contain about 1-20 carbon atoms and 0, 1 , 2, 3, 4 or 5 independent ⁇ selected heteroatoms, which are typically selected from oxygen, nitrogen, sulfur and phosphorus.
  • fewer intervening atoms are used when more rapid hydrolysis is desired, although larger structures are suitable if, e.g., they possess sufficient flexibility or have conformations to allow positioning of the carboxyl group in proximity to the amino acid-steroid bond.
  • R 22 is -H, methyl or hydroxym ethyl, usually -H
  • R 23 is a side chain or group of a naturally occurring amino acid.
  • Amino acid side chains include analogs where the side chain is a C ⁇ . 15 homolog of the corresponding natural compound, e.g., methylene, ethylene, propylene, butylene or a substituted derivative thereof, e.g., an alkyl, ether or alkoxy (e.g., methoxy, ethoxy, propoxy) substituted derivative.
  • carboxyl-containing side chains if the C atom of the side chain carboxyl is linked by 5 or less atoms to the N then the carboxyl optionally will be blocked, e.g. by esterification or amidation wherein the ester or amide bonds are hydrolyzable in vivo.
  • R 22 also is taken together with R 30 to form a proline residue (-CH2-)3-
  • R 23 is generally a side group such as -H, - CH 3 , -CH(CH 3 ) 2 , -CH 2 -CH(CH 3 )2, -CHCH3-CH2-CH3, -CH 2 -C 6 H 5 , -CH 2 CH 2 -S-CH 3 , - CH 2 OH, -CH(OH)-CH 3 , -CH 2 -SH, -CH 2 -C 6 H OH, -CH2-CO-NH 2 , -CH 2 -CH 2 -CO-NH 2 , -CH2-CO-NH 2 , -CH 2 -CH 2 -CO-NH 2 , -
  • R 23 also includes 1-guanidinoprop-3-yl, benzyl, 4-hydroxybenzyl, imidazol-4-yl, indol-3-yl, methoxyphenyl and ethoxyphenyl.
  • the optimal R 30 group is readily selected using routine assays.
  • the amino acid residue has the structure shown in the formulas below.
  • n is 1 or 2
  • R 22 is -H and R 23 is a moiety containing one or more of the following groups: amino, carboxyl, amide, carboxyl ester, hydroxyl, C6-C7 aryl, ether (-0-), thioether (-S-), n-, s- ort-alkyl (C ⁇ - CQ), guanidinyl, imidazolyl, indolyl, sulfhydryl, sulfoxide, and phosphoryl.
  • the R 22 and R 23 substituents can have a wide variety of structures including those disclosed herein, e.g., esters, ethers or carbonates.
  • D, L, meso, threo orerythro (as appropriate) racemates or mixtures thereof fall within the scope of this invention.
  • D isomers should be used.
  • L isomers may be more versatile since they can be susceptible to both non-enzymatic as well as potential targeted enzymatic hydrolysis, and are more efficiently transported by amino acid or dipeptidyl transport systems in the gastrointestinal tract.
  • amino acid residues include the following: Glycyl; aminopolycarboxylic acids, e.g., aspartic acid, ⁇ -hydroxyaspartic acid, glutamic acid, ⁇ - hydroxyglutamic acid, ⁇ -methylaspartic acid, ⁇ -methylglutamic acid, ⁇ , ⁇ -dimethylaspartic acid, ⁇ -hydroxyglutamic acid, ⁇ , ⁇ -dihydroxyglutamic acid, ⁇ -phenylglutamic acid, ⁇ - methyleneglutamic acid, 3-aminoadipicacid, 2-aminopimelic acid, 2-aminosuberic acid and 2-aminosebacic acid residues; amino acid amides such as glutaminyl and asparaginyl; polyamino- or polybasic-monocarboxylic acids such as arginine, lysine, ⁇ -aminoalanine, ⁇ - aminobutyrine, omithine, citruline, homoargin
  • amino acids are suitably employed in this invention.
  • amino acids are capable of autocatalytically hydrolyzing the amino acid-steroid bond.
  • they typically contain, or upon being hydrolyzed in vivo, contain a free carboxyl group or amine group.
  • hydrophobic amino acids such as mono-or di-alkyl or aryl amino acids, cycloalkylamino acids and the like.
  • R 29 - R 34 R 31 -R 34 are defined below
  • the residue does not contain a sulfhydryl or guanidino substituent.
  • Peptide means one, 2, 3 or more of the two or more amino acids as defined above are bonded together, usually by an amide bond.
  • Variable groups in the formula 1 compounds such as R 1 -R 10 can comprise a peptide.
  • the amino acids are linked through normal peptide bonds, e.g., -CO-NH-, between adjacent amino acid residues.
  • Peptides comprise dipeptides (di ers), tripeptides (tri ers), short peptides of 4, 5, 6, 8, 10 or 15 residues, and longer peptides or proteins having about 100 or more residues.
  • Formula 1 compounds that comprise a peptide can be used as immunogens, prodrugs or as synthetic precursors for other steroid derivatives.
  • the peptide will contain a peptidolytic enzyme cleavage site at the peptide bond linking the first residue and the next residue distal to the steroid residue.
  • Such cleavage sites are optionally flanked by enzymatic recognition structures, e.g. particular residues recognized by a hydrolytic enzyme, e.g., a peptidase located in the serum or in cells.
  • Peptidolytic enzymes are well known, and in particular include carboxypeptidases. Carboxypeptidases digest polypeptides by removing C-terminal residues, and are specific in many instances for particular C-terminal sequences. Such enzymes and their substrate requirements in general are well known.
  • a dipeptide having a given pair of residues and a free carboxyl terminus is covalently bonded through its ⁇ -amino group to the steroid nucleus. It is expected that the peptide will be cleaved by the appropriate dipeptidase, protease or by chemical hydrolysis, leaving the carboxyl of the proximal amino acid residue to autocatalytically cleave the amidate bond.
  • AA AR, AN, AD, AC, AE, AQ, AG, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, RA, RR, RN, RD, RC, RE, RQ, RG, RH, Rl, RL, RK, RM, RF, RP, RS, RT, RW, RY, RV, NA, NR, NN, ND, NC, NE, NQ, NG, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, DA, DR, DN, DD, DC, DE, DQ, DG, DH, DI, DL, DK, DM, DF, DP, DS, DT, DW, DY, DV, CA, CR, CN, CD, CC, CE, CQ, CG, CH, Cl, CL, CK, CM,
  • Such dipeptides include species where both amino acids are in the L configuration, the D configuration or mixtures of configurations.
  • Tripeptides i.e., 3 linked amino acid residues, are also useful embodiments.
  • Tripeptides include those where A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y is linked by a standard peptide bond to the amino or the carboxyl terminus of any of the dipeptides listed above.
  • the sequence -X1 -pro-X2- (where X1 is any amino acid and X2 is hydrogen, any amino acid residue or a carboxyl ester of proline) will be cleaved by luminal carboxypeptidase to yield X1 with a free carboxyl, which in turn autocatalytically cleaves the amidate bond.
  • X2 usually will be a benzyl ester of the carboxy group of X2.
  • Other embodiments include tetrapeptides such as ones where any two of the dipeptides listed above, which may be the same or different dipeptides (e.g., AA and AA linked together or, e.g., AA and Gl linked together), are linked to each other by a peptide bond through the amino terminus or carboxyl terminus.
  • One, 2 or more tetrapeptides may bonded to the formula 1 or formula 2 compound through the tetrapeptide's amino or carboxyl terminus.
  • the formula 1 or formula 2 compound comprises one or more amino acids or peptides having the structure (A), (B) or (C):
  • R 30 independently are the side chain of an amino acid, including the side chain of naturally occurring amino acids as described above, e.g., -H, -CH 3 , -CH 2 C 6 H 5 ;
  • R 31 is -H or a protecting group;
  • R 32 and R 33 independently comprise -H, a protecting group, an ester or an amide where each atom or group is independently chosen;
  • a, b, c and d independentV are 1 , 2, 3, 4 or 5, usually 1 ;
  • e, f and g independently are an integerfrom 0 to about 1000, typically they independentlyare 0, 1 , 2, 3, 4, 5, 6, 7 or 8;
  • a, b, c and d independently are 1 or 2;
  • e, f and g independently are 0, 1 , 2, 3, 4 or 5.
  • R 29 is usually -H and R 30 may comprise - [C(R 34 ) 2 ] n2 N(R PR )- where n2 is 0, 1 , 2, 3, 4, 5 or 6, R PR is -H or a protecting group and each R 34 independently is -H, C-
  • R 34 may comprise - [C(R 34 ) 2 ] n2 N(R PR )- where n2 is 0, 1 , 2, 3, 4, 5 or 6, R PR is -H or a protecting group and each R 34 independently is -H, C-
  • Such compounds will contain a plurality of steroid moieties.
  • steroid moieties For example when both the epsilon ( ⁇ ) or delta ( ⁇ ) and alpha ( ⁇ ) amino groups of lysine or ornithine are substituted with steroid moieties the amidate is believed to be capable of releasing two molecules of active drug, each expected to emerge under different pharmacokinetics and therefore further sustaining the drug release.
  • Salts of formula 1 compounds include salts and complexes of formula 1 compounds, including pharmaceutically acceptable or salts that are relatively non-toxic.
  • formula 1 compounds have one or more moieties that carry at least a partial positive or negative charge in aqueous solutions, typically at a pH of about 4-10, that can participate in forming a salt, a complex, a composition with partial salt and partial complex properties or other noncovalent interactions, all of which we refer to as a "salt(s)".
  • Salts are usually biologically compatible or pharmaceutically acceptable or non- toxic, particularly for mammalian cells. Salts that are biologically toxic are optionally used with synthetic intermediates of formula 1 compounds. When a water-soluble composition is desired, monovalent salts are usually used.
  • Metal salts typically are prepared by reacting the metal hydroxide with a compound of this invention.
  • metal salts that are optionally prepared in this way are salts containing Li + , Na + , and K + .
  • a less soluble metal salt can be precipitated from the solution of a more soluble salt by adding a suitable metal compound.
  • Invention salts may be formed from acid addition of certain organic acids, such as organic carboxylic acids, and inorganic acids, such as alkylsulfonic acids or hydrogen halide acids, to acidic or basic centers on formula 1 compounds, such as basic centers on the invention pyrimidine base analogs.
  • Metal salts include ones containing Na + , Li + , K + - Ca ++ or Mg ++ .
  • Salt(s) of formula 1 compounds may comprise a combination of appropriate cations such as alkali and alkaline earth metal ions or ammonium and quaternary ammonium ions with the acid anion moiety of the phosphoric acid or phosphonic acid group, which may be present in invention polymers or monomers.
  • Salts are produced by standard methods, including dissolving free base in an aqueous, aqueous-alcohol or aqueous-organic solution containing the selected acid, optionally followed by evaporating the solution.
  • the free base is reacted in an organic solution containing the acid, in which case the salt usually separates directly or one can concentrate the solution.
  • Suitable amine salts include amines having sufficient basicity to form a stable salt, usually amines of low toxicity including trialkyl amines (tripropylamine, triethylamine, trimethylamine), procaine, dibenzylamine, N-benzyl-betaphenethyiamine, ephenamine, N,N'- dibenzylethylenediamine, N-ethylpiperidine, benzylamine and dicyclohexylamine.
  • Salts include organic sulfonic acid or organic carboxylic acid salts, made for example by addition of the acids to basic centers, typically amines.
  • Exemplary sulfonic acids include C6-16 aryi sulfonic acids, C ⁇ -16 heteroaryl sulfonic acids and Ci-16 alkyl sulfonic acids such as phenyl sulfonic acid, a-naphthalene sulfonic acid, ⁇ -naphthalene sulfonic acid, (S)-camphorsulfonic acid, methyl (CH3SO3H), ethyl (C2H5SO3H), ⁇ -propyl, /-propyl, n-butyl, s-butyl, /-butyl, f-butyl, pentyl and hexyl sulfonic acids.
  • Exemplary organic carboxylic acids include Ci-16 alkyl, C6-16 aryl carboxylic acids and C .-I6 heteroaryl carboxylic acids such as acetic, glycolic, lactic, pyruvic, malonic, glutaric, tartaric, citric, fumaric, succinic, malic, maleic, oxalic, hydroxymaleic, benzoic, hydroxybenzoic, phenylacetic, cinnamic, salicylic, nicotinic and 2-phenoxybenzoic.
  • Invention salts include those made from inorganic acids, e.g., HF, HCl, HBr,
  • Suitable anions which are optionally present with a cation such a Ca ++ , Mg ++ , Li + , Na + or K + , include arsenate, arsenite formate, sorbate, chlorate, perchlorate, periodate, dichromate, glycodeoxycholate, cholate, deoxycholate, desoxycholate, taurocholate, taurodeoxycholate, taurolithocholate, tetraborate, nitrate, nitrite, sulfite, sulfamate, hyposulfite, bisulfite, metabisulfite, thiosulfate, thiocyanate, silicate, metasilicate, CN", gluconate, gulcuronate, hippurate, picrate, hydrosulfite,
  • Salts also include the formula 1 compound salts with one or more amino acids.
  • Many amino acids are suitable, especially the naturally-occurring amino acids found as protein components, although the amino acid typically is one bearing a side chain with a basic or acidic group, e.g., lysine, arginine, histidine or glutamic acid, or a neutral group such as glycine, serine, threonine, alanine, isoleucine, or leucine.
  • the invention compositions include formula 1 compounds, their hydrates and the compounds in their un-ionized, as well as zwitterionicform.
  • Stereoisomers are suitable, especially the naturally-occurring amino acids found as protein components, although the amino acid typically is one bearing a side chain with a basic or acidic group, e.g., lysine, arginine, histidine or glutamic acid, or a neutral group such as glycine, serine, threonine, alanine, is
  • the formula 1 compounds include enriched or resolved optical isomers at any or all asymmetric atoms as are apparent from the depictions. Both racemic and diasteromeric mixtures, as well as the individual optical isomers can be isolated or synthesized so as to be substantially free of their enantiomeric or diastereomeric partners, and these are all within the scope of the invention. Chiral centers may be found in formula 1 compounds at, for example, one or more of R 1 , R 2 , R 3 , R 4 or R 10 . [00155] One or more of the following methods are used to prepare the enantiomerically enriched or pure isomers herein.
  • stereospecific synthesis is described in the examples. Methods of this type conveniently are used when the appropriate chiral starting material is available and reaction steps are chosen do not result in undesired racemization at chiral sites.
  • One advantage of stereospecific synthesis is that it does not produce undesired enantiomers that must be removed from the final product, thereby lowering overall synthetic yield. In general, those skilled in the art would understand what starting materials and reaction conditions should be used to obtain the desired enantiomerically enriched or pure isomers by stereospecific synthesis.
  • Salts with such auxiliaries can be formed, or they can be covalently (but reversibly) bonded to the functional group.
  • pure D or L amino acids can be used to amidate the carboxyl group of invention embodiments that comprise a carboxyl group and then separated by chromatography.
  • Enzymatic resolution is another method of potential value. In such methods one prepares covalent derivatives of the enantiomers in the racemic mixture, generally lower alkyl esters (for example of carboxyl), and then exposes the derivative to enzymatic cleavage, generally hydrolysis. For this method to be successful an enzyme must be chosen that is capable of stereospecific cleavage, so it is frequently necessary to routinely screen several enzymes.
  • esters are to be cleaved, then one selects a group of esterases, phosphatases, and lipases and determines their activity on the derivative.
  • Typical esterases are from liver, pancreas or other animal organs, and include porcine liver esterase.
  • the enatiomeric mixture separates from solution or a melt as a conglomerate, i.e., a mixture of enantiomerically pure crystals, then the crystals can be mechanically separated, thereby producing the enantiomerically enriched preparation. This method, however, is not practical for large-scale preparations and is of limited value for true racemic compounds.
  • Asymmetric synthesis is another technique for achieving enantiomeric enrichment.
  • a chiral protecting group is reacted with the group to be protected and the reaction mixture allowed to equilibrate. If the reaction is enantiomerically specific then the product will be enriched in that enantiomer. [00162] Further guidance in the separation of enantiomeric mixtures can be found, by way of example and not limitation, in "Enantiomers, Racemates, and resolutions", Jean Jacques, Andre Collet, and Samuel H.
  • the peptide atone or more of R 1 -R 6 can comprise a cell surface binding peptide such as the entire protein or a sequence from fibronectin or retronectin.
  • each R 4 is independently selected. In some embodiments one R 4 is hydrogen and the other is another moiety. In other embodiments, both R 4 are independentV selected moieties other than hydrogen, e.g., a C1 to C20 organic moiety.
  • R 1 -R 6 , R 10 , R 15 , R 7 and R 18 include moieties, e.g., esters, thioesters, thionoesters, carbonates, amino acids, peptides and/or carbamates, that are chemically and/or enzymatically hydrolyzable, often under physiological conditions. Such moieties are independently chosen. Typically these moieties will give rise to -OH, -SH or -NH 2 at the R 1 - R 6 positions of the steroid nucleus.
  • Embodiments of formula 1 compounds include ones where (1) one of R 1 , R 2 and R 4 is a hydrolyzable moiety (e.g., ester, thioester, thionoester, carbonate, amino acid, peptide or carbamate), the other two of R 1 , R 2 and R 4 are -H, R 3 is not hydrogen and R 5 and R 6 are both -CH 3 , (2) two of R 1 , R 2 and R 4 are hydrolyzable moieties (e.g., independently chosen esters, thioesters, thionoesters, carbonates, amino acids, peptides and/or carbamates), the other of R 1 , R 2 and R 4 is -H, R 3 is not hydrogen and R 5 and R 6 are both -CH 3 , (3) R 1 , R 2 and R 4 are hydrolyzable moieties, R 3 is not hydrogen and R 5 and R 6 are both -CH 3 .
  • one of R 1 , R 2 and R 4 is
  • the R 3 group is typically in the ⁇ - configuration and the R ⁇ R 2 and R 4 -R 6 groups are typically in the ⁇ -configuration.
  • one or more of R 1 -R 6 , R 10 , R 15 , R 17 and R 18 usually one, comprises an amino acid or a peptide, while the remaining groups are independently selected from the moieties defined herein.
  • the peptides are typically dimers (dipeptides) or trimers (tripeptides).
  • R 1 , R 2 or R 4 comprises an amino acid
  • R 3 is a halogen, hydroxyl or an ester
  • R 5 and R 6 independently are -H, -(CH 2 ) n -CH 3 , -(CH 2 ) n -CH 2 OH, or -(CH 2 ) n -CH 2 F, -(CH 2 ) M -0-(CH 2 ) M - CH 3 , where n is 0, 1 , 2, 3, 4, 5, 6, 7 or 8 often 0, 1 , or 2, usually 0.
  • Hydrolyzable moieties typically comprise acyl groups, esters, ethers, thioethers, amides, amino acids, peptides, carbonates and/or carbamates.
  • the structure of hydrolyzable moieties is not critical and can vary. In some embodiments, these moieties contain a total of about 4 to about 10 carbon atoms.
  • hydrolyzable moieties in other embodiments comprise an organic moiety, as described above for ester, that contains 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12 13, 14, 15 or 16 carbon atoms and 1 , 2, 3, 4, 5, 6, 7 or 8 heteroatoms, e.g., oxygen, nitrogen or sulfur.
  • These hydrolyzable moieties can comprise no groups that are charged in plasma, blood, intracellular cytoplasm or in the gut, or they can comprise 1 , 2, 3 or more positive, negative or positive and negative charges under one or more of these conditions. The charges may be fractional depending on the group and the conditions it is under.
  • hydrolyzable moieties may comprise 1 , 2, 3, 4 or more substitutions at a hydrogen atom(s) and/or a carbon atom(s), e.g., -OH, protected hydroxyl, - SH, protected thiol, carboxyl, protected carboxyl, amine, protected amine, -0-, -S-, -CO-, - CS-, alkoxy, alkylthio, alkenyloxy, aryl, -OP(0)(0)-0-, -OS(0)(0)-0- and/or heterocycle.
  • substitutions are independentV selected.
  • Formula 1 compounds that comprise a hydrolyzable moiety(ies) may include one or more independently chosen -0-CHR 24 C(0)0R 25 , -S-CHR 24 C(0)OR 25 , -NH- CHR 24 C(0)OR 25 , -0-CHR 24 C(S)OR 25 , -S-CHR 24 C(S)OR 25 , -NH-CHR 24 C(S)OR 25 , -O- CHR 24 OC(0)R 25 , -S-CHR 24 OC(0)R 25 , -NH-CHR 24 OC(0)R 25 , -0-CHR 2 C(0)N(R 25 ) 2 , -S- CHR 24 C(0)N(R 25 ) 2 , -NH-CHR 24 C(0)N(R 25 ) 2 , -0-CHR 2 OR 25 , -S-CHR 24 OR 25 , -NH- CHR 24 OR 25 , -0-CHR 24 C(R 5 ) 2 CH 2 OX,
  • R 24 are -H, -CH 3 , -C 2 H 5 , -CH 2 -d. 5 optionally substituted alkyl, -CH 2 CH2-d. 4 optionally substituted alkyl and -CH 2 CH 2 -0-d. 4 optionally substituted alkyl.
  • R 25 independentlyis -H or a C 1 - 30 organic moiety such as -CH 2 -C 6 H 5 , -CH 2 CH 2 -C 6 H 5 , C1-12 alkyl, C 2 . 12 alkenyl, C 2 .
  • alkenyl or aryl are optionally independentlysubstituted with 3, 4, 5 or 6 halogens, where X is -H or a protecting group, or the aryl, heterocycle, -CH 2 -heterocycle or-CH 2 -aryl moieties are optionally independentlysubstituted with 1 , 2 or 3 C M alkyl moieties or with 1 , 2 or 3 C alkoxy moieties at the aryl moiety or at the heterocycle, usually at a ring carbon.
  • R 25 are -H, -CH3, -C 2 H5, -C3H7, -C 4 Hg, -C6H13, -dHs, -C6H4OH, -CeH 4 OCH3, -C ⁇ H F, -CH 2 -C ⁇ -5 optionally substituted alkyl, -CH 2 CH 2 -(S) 0 . ⁇ -C 1 ⁇ optionally substituted alkyl and -CH 2 CH 2 -0- d. 4 optionally substituted alkyl.
  • invention embodiments include a composition comprising (1 ) a compound of formula 1 or 2 and one or more nonaqueous liquid excipients, wherein the composition comprises less than about 3% v/v water and (2) a compound of formula 1 or 2 and one or more solid excipients.
  • invention embodiments include one or more compounds of formula 1 or formula 2 including formula 1 compounds having the structure
  • R ⁇ R 2 , R 3 , R 4 , R 5 , R 6 and R 10 independently are -H, -OR PR , -SR PR , -N(R PR ) 2 , -
  • R 3 and R 4 together comprise a structure of formula 2
  • R 7 is -C(R 10 ) 2 -, -C(R 10 ) 2 -C(R 10 ) 2 -, -C(R 10 ) 2 -C(R 10 ) 2 -C(R 10 ) 2 -, -C(R 10 ) 2 -O-
  • R 8 and R 9 independently are -C(R 10 ) 2 -, -C(R 10 ) 2 -C(R 10 ) 2 -, -0-, -O-C(R 10 ) 2 -, -S-,
  • R 8 and R 9 independently are -CHR 10 -, -CHR 10 -CHR 10 -, -0-, -O-CHR 10 -, -S-, -
  • S-CHR 10 -, -NR PR - or -NR PR -CHR 10 -, or R 8 or R 9 independentlyis absent, leaving a 5- membered ring;
  • R 13 independentlyis d. 6 alkyl
  • R PR independentlyis -H or a protecting group for, e.g., an O, N or S atom;
  • D comprises two 5- or 6-membered rings, wherein the rings are fused or are linked by 1 or 2 bonds, wherein one, two or three of R 7 , R 8 and R 9 are not -CHR 10 - or - C(R 10 ) 2 -.
  • R 7 , R 8 or R 9 is defined to include moieties such as -O-CHR 10 - or -NR PR -CHR 10 -, it is intended that such moieties can be present in either orientation relative to the other ring atoms that may be present, i.e., -O-CHR 10 -, -NR PR -CHR 10 -, -CHR 10 -O- and -CHR 10 -NR PR - are all included.
  • Embodiments of formula 1 compounds include or exclude any subset of compounds within the definition of formula 1 , provided that at least one compound remains.
  • a subset of formula 1 compounds that are may be included, for example in the invention nonaqueous formulations and in the inventbn intermittent dosing protocols and immune modulation methods are formula 1 compounds where R 2 is hydroxyl, or a group that can hydrolyze or metabolize to hydroxyl or thiol, in either configuration and R 5 and R 6 are methyl in the ⁇ -configuration.
  • a subset compounds that are optionally excluded from formula 1 compounds comprises one or all compounds that are disclosed in one or more prior art references or publications, e.g., one or more compounds that are disclosed in one or more of the references cited herein, especially for those compounds that can render any claim or embodiment unpatentablefor novelty, obviousness and/or inventive step reasons.
  • Exemplary embodiments of species and genera of formula 1 compounds are named as described below.
  • Group 1. Exemplary embodiments include the formula 1 compounds named according to the compound structure designations given in Tables A and B below. Each compound named in Table B is depicted as a compound having formula B B
  • R 5 and R 6 are both -CH 3 , there is no double bond atthe 1-2-, 4-5- or 5-
  • R 4 is hydrogen
  • R 7 , R 8 and R 9 are all -CH 2 - and R
  • R 2 , R 3 and R 4 are the substituents designated in Table A.
  • the compounds named according to Tables A and B are referred to as "group 1" compounds.
  • 10.8.9.9, 10.8.9.10 10.8.10.1, 10.8.10.2, 10.8.10.3, 10.8.10.4, 10.8.10.5, 10.8.10.6, 10.8.10.7, 10.8.10.8, 10.8.10.9, 10.8.10.10, 10.9.1.1, 10.9.1.2, 10.9.1.3, 10.9.1.4, 10.9.1.5, 10.9.1.6, 10.9.1.7, 10.9.1.8, 10.9.1.9,
  • Additional exemplary formula B compound groups include the following compound groups disclosed below. Unless otherwise specified, the configurations of all hydrogen atoms and R groups for the following compound groups are as defined for the group 1 compounds of formula B above.
  • Group 2 This group comprises compounds named in Table B having R 1 , R 2 ,
  • group 2 compound 1.3.1.1 has the structure
  • Group 3 This group comprises compounds named in Table B having R 1 , R 2 ,
  • group 3 compound 2.2.5.1 has the structure
  • Group 4 This group comprises compounds named in Table B having R 1 , R 2 ,
  • group 4 compound 5.2.7.8 has the structure
  • Group 5 This group comprises compounds named in Table B having R 1 , R 2 ,
  • Group 6 This group comprises compounds named in Table B having R 1 , R 2 ,
  • Group 7 comprises the 6 compound groups described above, except that R 5 is hydrogen instead of methyl, i.e., it comprises 6 subgroups, 7-1 , 7-2, 7-3, 7- 4, 7-5 and 7-6.
  • subgroup 7-1 has the same steroid nucleus as group 1 above, i.e., no double bond is present, but R 5 is -H.
  • Subgroup 7-2 comprises the same steroid nucleus as group 2 above, i.e., a double bond is present at the 5-6-position, but R 5 is -H.
  • Compound subgroups 7-3 through 7-6 are assigned a steroid nucleus in the same manner.
  • the subgroup 7-1 through subgroup 7-6 compounds named 1.2.1.9 have the structures
  • Group 8 comprises 6 subgroups of compounds, i.e., each compound named in groups 1-6, except that R 5 of formula B is -CH 2 OH instead of methyl.
  • the subgroups 8-1 through subgroup 8-6 compounds have structures that are named in the same manner as group 1-6 compounds, except that -CH 2 OH instead of methyl is present at R 5 .
  • These groups are named in essentially the same manner as subgroups 7-1 through 7-6.
  • subgroup 8-1 and subgroup 8-2 compounds named 1.2.1.9 have the structures
  • Group 9 comprises each compound named in compound groups 1-
  • group 9 comprises subgroups 9-1 through 9-8-6, i.e., 9-1 , 9-2, 9-3, 9-4, 9-5, 9-6, 9-7-1 , 9-7-2, 9-7-3, 9-7-4, 9-7- 5, 9-7-6, 9-8-1 , 9-8-2, 9-8-3, 9-8-4, 9-8-5 and 9-8-6.
  • Subgroups 9-1 through 9-8-6 compounds have structures that are named in essentially the same manner as subgroup 7-1 through 7-6 compounds, except that -H instead of methyl is present at R 6 .
  • subgroup 9- 1 and subgroup 9-2 compounds named 1.2.1.9 have the structures subgroup 9-1 compound 1.2.1.9, and
  • Subgroup 9-7-1 compound 1.2.1.9 has the same structure as group 9-1 compound 1.2.1.9, except that R 5 is hydrogen in the ⁇ configuration, instead of a methyl group in the ⁇ configuration.
  • the group 9-8-1 compound 1.2.1.9 has the same structure as group 9-1 compound 1.2.1.9, except that R 5 is hydroxymethyl (-CH 2 OH) in the ⁇ configuration, instead of a methyl group in the ⁇ configuration.
  • Group 9-7-2 compound 1.2.1.9 has the same structure as the group 9-7-1 compound, except that a double bond is present at the 5-6 position.
  • subgroups 9-1 through 9-6 have hydrogen at R 6 , but each has a different double bond structure, e.g., no double bond in subgroup 9-1 and double bonds at 1- 2 and 4-5 in subgroup 9-6.
  • Subgroups 9-7-1 through 9-7-6 also comprises six subgroups, but they have hydrogen at R 5 and R 6 , but each has a different double bond structure for each of the six subgroups, e.g., no double bond in subgroup 9-7-1 and double bonds at positions 1-2 and 4-5 in subgroup 9-7-6.
  • Subgroups 9-8-1 through 9-8-6 all have hydrogen at R 6 and -CH 2 OH at R 5 , but each has a different double bond structure in each, e.g., no double bond in subgroup 9-8-1 and double bonds at positions 1-2 and 4-5 in group 9-8-6.
  • Groups 10. Group 10 comprises each compound named in groups 1 through
  • subgroups 10-1 through group 10-6 compounds have structures that are named in essentially the same manner as compounds in group 9, except that -CH 2 OH instead of methyl is present at R 6 .
  • subgroup 10-1 and subgroup 10-2 compounds named 1.2.1.9 have the structures 10-1 compound 1.2.1.9, and
  • Subgroup 10-7-1 compound 1.2.1.9 has the same structure as subgroup 10-1 compound 1.2.1.9, except that R 5 is hydrogen in the ⁇ configuration, instead of a methyl group in the ⁇ configuration.
  • the subgroup 10-8-1 compound 1.2.1.9 has the same structure as group 10-1 compound 1.2.1.9, except that R 5 is hydroxymethyl (-CH 2 OH) in the ⁇ configuration, instead of a methyl group in the ⁇ configuration.
  • Subgroup 10-7-2 compound 1.2.1.9 has the same structure as the subgroup 10-7-1 compound, except that a double bond is present at the 5-6 position.
  • subgroups 10-1 through 10-8-6 comprise 18 separate groups, each of which has -CH 2 OH at R 6 .
  • Subgroups 10-1 through 10-6 comprise different six subgroups where each has a different double bond structure, e.g., no double bond in subgroup 10-1 and double bonds at 1-2 and 4-5 in subgroup 10-6.
  • Subgroups 10-7-1 through 10-7-6 all have -CH 2 OH at R 6 and hydrogen at R 5 , but each has a different double bond structure for each of the six groups, e.g., no double bond in subgroup 10-7-1 and double bonds at positions 1-2 and 4-5 in subgroup 10-7-6.
  • subgroups 10-8-1 through 10-8-6 al six have -CH 2 OH at R 6 and at R 5 , but each has a different double bond structure in each of the six subgroups, e.g., no double bond in subgroup 10-8-1 and double bonds at positions 1-2 and 4-5 in subgroup 10-8-6.
  • the 18 groups are 10-1 , 10-2, 10-3, 10-4, 10-5, 10-6, 10-7-1 , 10-7-2, 10-7-3, 10-7-4, 10-7-5, 10-7-6, 10-8-1, 10-8-2, 10-8-3, 10-8-4, 10-8-5 and 10-8-6.
  • Group 11 comprises each compound named in compound groups
  • subgroup 11-1 through subgroup 11-6 oompounds have structures that are named in essentially the same manner as described for the groups above, except that moieties 1 -10 of table A are replaced by the moieties 1 -10 at R 1 .
  • subgroup 11 -1 and 11-2 compounds named 1.2.1.9 have the structures
  • Subgroup 11-7-1 and 11-7-2 compounds named 1.2.1.9 have the structures
  • Subgroup 11-8-1 and 11-8-2 compounds named 1.2.1.9 have the structures
  • Group 11 comprises 54 separate subgroups, subgroups 11-1 through 11-10- 8-6, where each of which has the R 1 moieties shown in this group and the remaining moieties as shown in the other groups described above.
  • Subgroups 11-1 through 11-6 each have a different double bond structure, e.g., no double bond in subgroup 11-1 and double bonds at 1-2 and 4-5 in subgroup 11-6.
  • Subgroups 11-7-1 through 11-7-6 all have -CHjDH at R 6 and hydrogen at R 5 , but each has a different double bond structure, e.g., no double bond in subgroup 11-7-1 and double bonds at positions 1-2 and 4-5 in subgroup 11-7-6.
  • Subgroups 11-8-1 through 11-8-6 comprise all have -CH 2 OH at R 6 and at R 5 , but each has a different double bond structure in each of the six groups, e.g., no double bond in group 11-8- 1 and double bonds at positions 1-2 and 4-5 in group 11 -8-6.
  • the compounds in the remaining groups are named in essentially the same manner. [00209]
  • the 54 groups are 11 -1 , 11-2, 11-3, 11-4, 11-5, 11-6, 11-7-1 , 11-7-2, 11-7-3, .
  • Group 12 comprises each compound named in groups 1 through 10, but where R 1 moieties 1-10 listed in Table A are replaced with the following moieties:
  • Group 12 comprises 54 separate subgroups, subgroups 12-1 through 12-10-
  • the subgroups are defined essentially as described for group 11 above.
  • the 54 subgroups are 12-1 , 12-2, 12-3, 12-4, 12-5, 12-6, 12-7-1 , 12-7-2, 12-7-3, 12-7-4, 12-7-5, 12-7-6, 12-8-1 , 12-8-2, 12-8-3, 12-8-4, 12-8-5, 12-8-6, 12-9-1 , 12-9-2, 12-9-3, 12-9-4, 12-9-5, 12-9-6, 12-10-1 , 12-10-2, 12-10-3, 12-10-4, 12-10-5, 12-10-6, 12-9-7-1 , 12-9-7-2, 12-9-7-3, 12-9-7-4, 12-9-7-5, 12-9-7-6, 12-10- 7-1 , 12-10-7-2, 12-10-7-3, 12-10-7-4, 12-10-7-5, 12-10-7-6, 12-10- 7-1 , 12-10-7-2, 12-10-7-3, 12-10-7-4, 12-10-7-5, 12-10-7-6, 12-9-8-1 , 12-9-8-2, 12-9-8-3, 12- 9-8
  • Group 13 comprises each compound named in groups 1 through
  • 3 -O-polyethylene glycol e.g., PEG20, PEG100, PEG200 or PEG400
  • R 42 is -H, C2-C6 alkyl or an amino acid side chain
  • Group 13 comprises 54 separate subgroups, subgroups 13-1 through 13-10- 8-6, where each of which has the R 1 moieties shown in this group and the remaining moieties as shown in the other groups described above.
  • the subgroups are defined essentially as described for group 11 above.
  • the 54 subgroups are 13-1 , 13-2, 13-3, 13-4, 13-5, 13-6, 13-7-1 , 13-7-2, 13-7-3, 13-7-4, 13-7-5, 13-7-6, 13-8-1 , 13-8-2, 13-8-3, 13-8-4, 13-8-5, 13-8-6, 13-9-1, 13-9-2, 13-9-3, 13-9-4, 13-9-5, 13-9-6, 13-10-1 , 13-10-2, 13-10-3, 13-10-4, 13-10-5, 13-10-6, 13-9-7-1 , 13-9-7-2, 13-9-7-3, 13-9-7-4, 13-9-7-5, 13-9-7-6, 13-10- 7-1 , 13-10-7-2, 13-10-7-3, 13-10-7-4, 13-10-7-5, 13-10-7-6, 13-9-8-1 , 13-9-8-2, 13-9-8-3, 13- 9-8-4, 13-9-8-5, 13-9-8-6, 13-10-8-1 , 13-10-8-2, 13-10-8-3, 13-10-84, 13-10-8-5 and 13-10- 8-6.
  • Group 14 comprises each compound named in groups 1 through
  • Group 14 comprises 54 separate subgroups, subgroups 14-1 through 14-10-
  • Group 15 comprises each compound named in groups 1 through
  • Group 15 comprises 54 separate subgroups, subgroups 15-1 through 15-10-
  • 15-10-4 15-10-5, 15-10-6, 15-9-7-1, 15-9-7-2, 15-9-7-3, 15-9-74, 15-9-7-5, 15-9-7-6, 15-10-
  • Group 16 comprises each compound named in groups 1 through
  • A4-NH 2 is a 4 carbon alkyl group substituted with -NH 2 (-0-C(0)-A4-NH 2 replaces -OH, which is R 1 moiety 1 in Table A) 2 -0-C(0)-A6-NH 2 , where A6-NH 2 is a 6 carbon alkyl group substituted with -NH 2
  • A8-NH 2 is a 8 carbon alkyl group substituted with
  • A4-OH is a 4 carbon alkyl group substituted with -OH or -O- 5 -0-C(0)-A6-OH, where A6-OH is a 6 carbon alkyl group substituted with -OH or -O-
  • A8-OH is a 8 carbon alkyl group substituted with -OH or -O-
  • Group 16 comprises 54 separate subgroups, subgroups 16-1 through 16-10-
  • the 54 subgroups are 16-1 , 16-2, 16-3, 16-4, 16-5, 16-6, 16-7-1 , 16-7-2, 16-7-3, 16-7-4, 16-7-5, 16-7-6, 16-8-1, 16-8-2, 16-8-3, 16-84, 16-8-5, 16-8-6, 16-9-1 , 16-9-2, 16-9-3, 16-94, 16-9-5, 16-9-6, 16-10-1 , 16-10-2, 16-10-3, 16-10-4, 16-10-5, 16-10-6, 16-9-7-1 , 16-9-7-2, 16-9-7-3, 16-9-74, 16-9-7-5, 16-9-7-6, 16-10- 7-1 , 16-10-7-2, 16-10-7-3, 16-10-74, 16-10-7-5, 16-10-7-6, 16-9-8-1 , 16-9-8-2, 16-9-8-3, 16- 9-8-4,
  • Group 17 comprises each compound named in compound groups
  • R 44 is H, NH 4 + , Na + , K + , HN + (CH 3 ) 3 , N + (CH 3 ) 4 , HN + (C 2 H 5 ) 3 C1-C8 alkyl ,(e.g., -CH 3 , -C 2 H 5 or -C 3 H 7 ), or pyridinium + ) 6 -0-P(0)(OH)-OR 44
  • Group 17 comprises 54 separate subgroups, subgroups 17-1 through 17-10-
  • Group 18 comprises each compound named in groups 1 through
  • Group 18 comprises 432 separate subgroups, 18-1 through 18-17-10-8-6, where each of which has the R 4 moieties shown in this group and the remaining moieties as shown in the other groups described above. These groups are defined essentially as described for the groups described above.
  • the groups are 18-1 through 18-6, 18-7-1 through 18-7-6, 18-8-1 through 18-8-6, 18-9-1 through 18-9-6, 18-10-1 through 18-10-6, 18- 9-7-1 through 18-9-7-6, 18-9-8-1 through 18-9-8-6, 18-10-7-1 through 18-10-7-6, 18-10-8-1 through 18-10-8-6, 18-11-1 tirough 18-11-6, 18-11-7-1 tirough 18-11-7-6, 18-11-8-1 through 18-11-8-6, 18-11-9-1 tirough 18-11-9-6, 18-11-10-1 through 18-11-10-6, 18-11-9-7- 1 through 18-11-9-7-6, 18-11-9-8-1 through 18-11-9-8-6, 18-11-10-7-1 through 18-11-10-7- 6, 18-11-10-8-1 through 18-11-10-8-6, 18-12-1 through 18-12-6, 18-12-7-1 through 18-12-7- 6, 18-12-8-1 through 18-12-8-6, 18-12-9-1 through 18-12-9-6, 18-12-10-1 through 18-12-10- 6, 18-12-9-7-1 through 18-12-9-7-6, 18-12-9-7-1 through 18-12-9-6, 18
  • Group 19 comprises 432 separate subgroups, 19-1 through 19-17-10-8-6, where each of which has the R 4 moieties shown in this group and the remaining moieties as shown in the other groups described above. These subgroups are defined essentially as described for group 18 above. The subgroups are 19-1 through 19-6, 19-7-1 Aliston 19-7-6,
  • Group 20 comprises each compound named in groups 1 through
  • R 44 is H, NH 4 + , Na + , K + , HN + (CH 3 ) 3 , N + (CH 3 ) 4 , HN + (C 2 H 5 ) 3 C1-C8 optionally substituted alkyl (e.g., -CH 3 , -C 2 H 5 or -C 3 H 7 ), or pyridinium + )
  • Group 20 comprises 432 separate subgroups, 20-1 through 20-17-10-8-6 comprise 432 separate groups, each of which has the R 4 moieties defined for this group and the remaining moieties as shown in the other groups described above. These subgroups are defined essentially as described for group 18 above. The subgroups are 20-1 through 20-6, 20-7-1 through 20-7-6,20-8-1 through 20-8-6,20-9-1 through 20-9-6 and so on essentially as described for group 18 compounds.
  • Group 21 comprises each compound named in compound groups
  • R 42 is -H, C2-C6 alkyl or an amino acid side chain
  • 10 -O-polyethylene glycol e.g., PEG20, PEG100, PEG200 or PEG400
  • Group 21 comprises 432 separate subgroups, 21-1 through 21-17-10-8-6 . comprise 432 separate groups, each of which has the R 4 moieties defined for this group and the remaining moieties as shown in the other groups described above. These subgroups are defined essentially as described for group 18 above. The subgroups are 21-1 through 21-6,
  • Group 22 comprises each compound named in compound groups
  • Group 22 comprises subgroups 22-1 through 22-21-17-10-8-6, which name compounds or genera of compounds essentially as described for the other compound groups above.
  • the 1728 subgroups in group 22 are 22-1 through 22-6, 22-7-1 through 22-7- 6, 22-8-1 through 22-8-6, 22-9-1 through 22-9-6 and so on essentially as described for the groups above.
  • Group 23 comprises each compound named in compound groups
  • Group 23 comprises subgroups 24-1 through 24-23-21 -17-10-8-6, which name compounds or genera of compounds essentially as described for the other compound groups above.
  • the subgroups in group 24 are 24-1 through 24-6, 24-7-1 through 24-7-6, 24- 8-1 through 24-8-6, 24-9-1 through 24-9-6 and so on essentially as described for the groups above.
  • Group 24. Group 24 comprises each compound named in compound groups
  • Group 24 comprises subgroups 23-1 through 23-21-17-10-8-6, which name compounds or genera of compounds essentially as described for the other compound groups above.
  • the 1728 subgroups in group 23 are 23-1 through 23-6, 23-7-1 through 23-7- 6, 23-8-1 through 23-8-6, 23-9-1 through 23-9-6 and so on essentially as described for the groups above.
  • Group 25 comprises each compound named in compound groups
  • Group 25 comprises subgroups 25-1 through 25-23-21-17-10-8-6, which name compounds or genera of compounds essentially as described for the other compound groups above.
  • the subgroups in group 25 are 25-1 through 25-6, 25-7-1 through 25-7-6, 25- 8-1 through 25-8-6, 25-9-1 through 25-9-6 and so on essentially as described for the groups above.
  • Group 26 is
  • Group 26 comprises subgroups 26-1 through 26-25-23-21-17-10-8-6, which name compounds or genera of compounds essentially as described for the other compound groups above.
  • the subgroups in group 26 are 26-1 through 26-6, 26-7-1 through 26-7-6, 26- 8-1 through 26-8-6, 26-9-1 through 26-9-6 and so on essentially as described for the groups above.
  • Group 27 comprises subgroups 27-1 through 27-26-25-23-21-17-10-8-6, which name compounds or genera of compounds essentially as described for the other compound groups above. The subgroups in group 27 are 27-1 through 27-6, 27-7-1 through 27-7-6, 27-8-1 through 27-8-6, 27-9-1 through 27-9-6 and so on essentially as described for the groups above.
  • Group 28 comprises subgroups 28-1 through 28-27-26-25-23-21-17-10-8-6, which name compounds or genera of compounds essentially as described for the other compound groups above.
  • the subgroups in group 28 are 28-1 through 28-6, 28-7-1 through 28-7-6, 28-8-1 through 28-8-6, 28-9-1 through 28-9-6 and so on essentially as described for the groups above.
  • Group 29 comprises subgroups 29-1 through 29-28-27-26-25-23-21-17-10-8-
  • Group 30 comprises each compound or genus named in compound groups 1 through 29, but wherein R 5 is in the ⁇ -configuration, instead of the ⁇ - configuration as shown in formula B.
  • Group 30 comprises subgroups 30-1 through 30-29-28-27-26-25-23-21-17-
  • 10-8-6 which name compounds or genera of compounds essentially as described for the other compound groups above.
  • the subgroups in group 30 are 30-1 through 30-6, 30-7-1 through 30-7-6, 30-8-1 through 30-8-6, 30-9-1 through 30-9-6 and so on essentially as described for the groups above.
  • Group 31 comprises each compound or genus named in compound groups 1 through 30, but wherein R 5 is in the ⁇ -configuration, instead of the ⁇ - configuration as shown in formula B.
  • Group 31 comprises subgroups 31-1 through 31-30-29-28-27-26-25-23-21-
  • 17-10-8-6 which name compounds or genera of compounds essentially as described for the other compound groups above.
  • the subgroups in group 31 are 31-1 through 31-6, 31-7-1 through 31-7-6, 31-8-1 through 31-8-6, 31-9-1 through 31-9-6 and so on essentially as described for the groups above.
  • Group 32 comprises each compound or genus named in compound groups 1 through 31 , but wherein the hydrogen atom at the 5 position is in the ⁇ - configuration, instead of the ⁇ -configuration as shown in formula B.
  • Group 32 comprises subgroups 32-1 through 32-31-30-29-28-27-26-25-23- 21-17-10-8-6, which name compounds or genera of compounds essentially as described for the other compound groups above.
  • the subgroups in group 32 are 32-1 through 32-6, 32-7- 1 through 32-7-6, 32-8-1 through 32-8-6, 32-9-1 through 32-9-6 and so on essentially as described for the groups above.
  • Group 33 comprises each compound or genus named in compound groups 1 through 31 , but wherein the hydrogen atom at the 5 position is in the ⁇ - configuration, instead of the ⁇ -configuration as shown in formula B.
  • Group 32 comprises subgroups 32-1 through 32-31-30-29-28-27-26-25-23- 21-17-10-8-6, which name compounds or genera of compounds essentially as described for the other
  • Group 33 comprises each compound or genus named in compound groups 1 through 32, but wherein the hydrogen atom at the 8 position is in the ⁇ - configuration, instead of the ⁇ -configuration as shown in formula B. [00255] Group 33 comprises subgroups 33-1 through 33-32-31-30-29-28-27-26-25-
  • 23-21-17-10-8-6 which name compounds or genera of compounds essentially as described for the other compound groups above.
  • the subgroups in group 33 are 33-1 through 33-6, 33-7-1 through 33-7-6, 33-8-1 through 33-8-6, 33-9-1 through 33-9-6 and so on essentially as described for the groups above.
  • Group 34 comprises each compound or genus named in compound groups 1 through 33, but wherein the hydrogen atom at the 9 position is in the ⁇ - configuration, instead of the ⁇ -configuration as shown in formula B. [00257] Group 34 comprises subgroups 34-1 through 34-33-32-31-30-29-28-27-26-
  • Group 35 comprises each compound or genus named in compound groups 1 through 34, but wherein the hydrogen atom atthe 14 position is in the ⁇ -configuration, instead of the ⁇ -configuration as shown in formula B.
  • Group 35 comprises subgroups 35-1 through 35-34-33-32-31-30-29-28-27- 26-25-23-21-17-10-8-6, which name compounds or genera of compounds essentially as described for the other compound groups above.
  • the subgroups in group 35 are 35-1 through 35-6, 35-7-1 through 35-7-6, 35-8-1 through 35-8-6, 35-9-1 through 35-9-6 and so on essentially as described for the groups above.
  • Group 36 comprises each compound or genus named in compound groups 1 through 35, but wherein R 4 in formula B is not divalent, and a second monovalent R 4 is present at the 17 position, and the second R 4 is a moiety other than hydrogen.
  • monovalent R 4 means that the second R 4 moiety is bonded to the carbon atom at the 17 position by a single bond.
  • the second R 4 optionally comprises -OH, -OR PR , -SH, -SR PR , -NH 2 , -NHR PR , a halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted alkylaryl, an optionally substituted heterocycle, an ester, an ether, a thioester, a thionoester, a thioether, an optionally substituted monosaccharide, an optionally substituted oligosaccharide, a carbonate, a carbamate, an amide or an amino acid. Any of these moieties, may comprise any R 4 structure disclosed herein.
  • Exemplary second R 4 moieties include -C ⁇ C-(CH 2 ) n H (e.g., -C ⁇ CH and -C ⁇ C-

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)

Abstract

La présente invention concerne l'utilisation de composés permettant de traiter plusieurs troubles tels que la thrombocytopénie, la neutropénie, ou les effets à retardement de la radiothérapie. Les composés convenant dans le cadre de l'invention sont à base de méthyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ène-3β-yl)-β-D-glucopyranosiduronate.
EP02709780A 2001-03-01 2002-03-01 Traitement de d ficiences affectant les globules sanguins Ceased EP1372664A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP09172321A EP2135611A1 (fr) 2001-03-01 2002-03-01 Derivés de Pregn-5-en-20-yn-3,7,17-triol pour utilisation thérapeutique

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US27262401P 2001-03-01 2001-03-01
US272624P 2001-03-01
US09/820,483 US20030060425A1 (en) 1998-11-24 2001-03-29 Immune modulation method using steroid compounds
US820483 2001-03-29
US32301601P 2001-09-10 2001-09-10
US323016P 2001-09-10
US32873801P 2001-10-11 2001-10-11
US328738P 2001-10-11
US34005401P 2001-11-01 2001-11-01
US340054P 2001-11-01
US33801501P 2001-11-08 2001-11-08
US338015P 2001-11-08
US34352301P 2001-12-20 2001-12-20
US343523P 2001-12-20
PCT/US2002/006708 WO2002069977A1 (fr) 2001-03-01 2002-03-01 Traitement de déficiences affectant les globules sanguins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP09172321A Division EP2135611A1 (fr) 2001-03-01 2002-03-01 Derivés de Pregn-5-en-20-yn-3,7,17-triol pour utilisation thérapeutique

Publications (1)

Publication Number Publication Date
EP1372664A1 true EP1372664A1 (fr) 2004-01-02

Family

ID=27569546

Family Applications (2)

Application Number Title Priority Date Filing Date
EP09172321A Withdrawn EP2135611A1 (fr) 2001-03-01 2002-03-01 Derivés de Pregn-5-en-20-yn-3,7,17-triol pour utilisation thérapeutique
EP02709780A Ceased EP1372664A1 (fr) 2001-03-01 2002-03-01 Traitement de d ficiences affectant les globules sanguins

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP09172321A Withdrawn EP2135611A1 (fr) 2001-03-01 2002-03-01 Derivés de Pregn-5-en-20-yn-3,7,17-triol pour utilisation thérapeutique

Country Status (5)

Country Link
EP (2) EP2135611A1 (fr)
JP (1) JP2004537506A (fr)
AU (2) AU2002244247B2 (fr)
CA (1) CA2439687A1 (fr)
WO (1) WO2002069977A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7893044B2 (en) * 1995-02-24 2011-02-22 Epigenesis Pharmaceutical, Inc. Composition and method for altering levels of or sensitivity to adenosine with analogs of dehydroepiandrosterone
WO2009158713A1 (fr) * 2008-06-27 2009-12-30 The Trustees Of The University Of Pennsylvania Procédés d'utilisation d'un composé de méthylxanthine
US9155741B2 (en) 2000-08-01 2015-10-13 The Trustees Of The University Of Pennsylvania Methods of using a methylxanthine compound
FR2831441B1 (fr) * 2001-10-25 2003-12-26 Oreal Utilisation cosmetique de derives de la dhea
JP2005529141A (ja) * 2002-05-01 2005-09-29 アーサー シュワルツ、 ７−ヒドロキシ−１６α−フルオロ−５−アンドロステン−１７−オン類および７−ヒドロキシ−１６α−フルオロ−５−アンドロスタン−１７−オン類およびそれらの誘導体
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
US8569275B2 (en) 2002-08-28 2013-10-29 Harbor Therapeutics, Inc. Steroids having 7-oxgen and 17-heteroaryl substitution
JP2006506445A (ja) 2002-08-28 2006-02-23 ホリス − イーデン ファーマスーティカルズ、 インコーポレイテッド 治療処置の方法
CA2522784C (fr) 2003-04-01 2012-06-19 Hollis-Eden Pharmaceuticals, Inc. Antiandrogenes presentant une activite agoniste marginale, et methodes d'utilisation
EP2468282A3 (fr) 2005-07-12 2012-09-12 DMI Biosciences, Inc. Procédés et produits de traitement des maladies
DK2486924T3 (en) * 2006-04-22 2019-03-04 Neurmedix Inc Medicines and uses
US8486926B2 (en) 2006-11-17 2013-07-16 Harbor Therapeutics, Inc. Steroid tetrol solid state forms
US8354396B2 (en) 2006-11-17 2013-01-15 Harbor Therapeutics, Inc. Drug identification and treatment method
US8217025B2 (en) 2006-11-17 2012-07-10 Harbor Therapeutics, Inc. Drug screening and treatment methods
PL2097079T3 (pl) * 2006-11-30 2012-11-30 Hunter Fleming Ltd Modulowanie szlaków metabolicznych prostaglandyna/cyklooksygenaza
SG2014008171A (en) 2009-06-22 2014-04-28 Ampio Pharmaceuticals Inc Method for treatment of diseases
SG10201705044YA (en) 2012-12-19 2017-07-28 Ampio Pharmaceuticals Inc Method for treatment of diseases
JP6077880B2 (ja) * 2013-02-18 2017-02-08 株式会社ファンケル ＴＮＦ−α産生抑制剤
CN108314698A (zh) * 2017-01-17 2018-07-24 刘珂 原人参二醇磷酸酯钠及其制备和其单独或多药联合在治疗肾病综合症中的应用
WO2020247366A1 (fr) * 2019-06-05 2020-12-10 University Of Georgia Research Foundation Compositions et procédés de prévention ou de traitement de l'hypertension artérielle pulmonaire associée au virus de l'immunodéficience humaine
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
CN111024843B (zh) * 2019-12-18 2022-06-21 大连医科大学附属第一医院 用于诊断帕金森病的联合标志物及检测试剂盒

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2170124A (en) 1935-12-07 1939-08-22 Schering Ag Compounds of the androstane and pregnane series and methods of producing the same
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3984566A (en) 1974-02-25 1976-10-05 Scott Eugene J Van Method of alleviating the symptoms of dandruff
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
GB1523965A (en) 1976-03-19 1978-09-06 Ici Ltd Pharmaceutical compositions containing steroids
US4234599A (en) 1978-10-04 1980-11-18 Scott Eugene J Van Treatment of skin keratoses with α-hydroxy acids and related compounds
US4246261A (en) 1979-08-09 1981-01-20 Scott Eugene J Van Additives enhancing topical corticosteroid action
WO1981002671A1 (fr) 1980-03-20 1981-10-01 Ferring Farma Lab Composition pharmaceutique et methode de traitement de la colite ulcereuse et la maladie de crohn par voie orale
US4652443A (en) 1983-06-07 1987-03-24 Japan Atomic Energy Research Institute Slow-release composite and process for producing the same
US4602008A (en) * 1984-12-14 1986-07-22 Progenics, Inc. Alkylated etiocholanolones and use as an anti-diabetic, anti-obesity and erythropoietic agent
DK173704B1 (da) 1985-04-17 2001-07-09 Hoffmann La Roche Fremgangsmåde til katalytisk oxidation af allyliske grupper
JPS6261916A (ja) 1985-09-12 1987-03-18 Fujisawa Pharmaceut Co Ltd 持続性製剤
US5188840A (en) 1985-09-26 1993-02-23 Chugai Seiyaku Kabushiki Kaisha Slow-release pharmaceutical agent
US5869698A (en) 1986-07-17 1999-02-09 Board Of Governors Of Wayne State University 1,2-dioxetane compounds as chemiluminescent labels for organic and biological molecules
MX9203808A (es) 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
US5811118A (en) 1987-05-22 1998-09-22 The Liposome Company, Inc. Methods of treatment using unilamellar liposomal arachidonic acid metabolite formulations
DE3801229A1 (de) 1988-01-18 1989-07-27 Krupp Polysius Ag Mahlverfahren sowie mahlanlage
US5043165A (en) 1988-12-14 1991-08-27 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs
US5262407A (en) 1988-12-16 1993-11-16 L'oreal Use of salicylic derivatives for the treatment of skin aging
US5407684A (en) 1988-12-30 1995-04-18 Virginia Commonwealth University Use of DHEA as a medicinal
US5461042A (en) 1988-12-30 1995-10-24 Loria; Roger M. Regulation of the immune system
US5128450A (en) 1989-06-30 1992-07-07 Urdal David L Nonglycosylated human interleukin-3 analog proteins
JP2642486B2 (ja) 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
AU652130B2 (en) 1989-09-25 1994-08-18 University Of Utah Research Foundation Use of steroid hormones in compositions for inducing T cell lymphokine production
US5837269A (en) 1989-09-25 1998-11-17 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
US5753237A (en) 1989-09-25 1998-05-19 University Of Utah Research Foundation Method for augmenting immunological responses
US5882678A (en) 1990-01-12 1999-03-16 The Liposome Co, Inc. Interdigitation-fusion liposomes containing arachidonic acid metabolites
US5820848A (en) 1990-01-12 1998-10-13 The Liposome Company, Inc. Methods of preparing interdigitation-fusion liposomes and gels which encapsulate a bioactive agent
US5641766A (en) 1990-08-29 1997-06-24 Humanetics Corporation UP-regulation of immune system with Δ 5-Androstenes
US5585371A (en) 1990-08-29 1996-12-17 Humanetics Corporation Treatment of immune system with Δ5-androstenes
US5292730A (en) 1990-08-29 1994-03-08 Humanetics Corporation Modulation of immune system with Δ5-androstenes
US6605712B1 (en) 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
US5162198A (en) 1991-02-08 1992-11-10 Virginia Commonwealth University Method of using dehydroepiandrosterone and dehydroepiandrosterone-sulfate as inhibitors of thrombuxane production and platelet aggregation
US5254343A (en) 1991-03-19 1993-10-19 Bristol-Myers Squibb Company Reduction of cutaneous atrophy
US5271944A (en) 1991-04-05 1993-12-21 Biofor, Ltd. Pharmacologically enhanced formulations
US5206008A (en) 1991-04-15 1993-04-27 Virginia Commonwealth University Enhancement of immune response
US5837840A (en) 1993-09-20 1998-11-17 Board Of Trustees Of Leland Stanford Jr. University NF-AT polypeptides and polynucleotides
CA2114434A1 (fr) 1991-08-22 1993-03-04 William M. Flanagan Methodes de criblage d'agents immunosuppresseurs
US5461768A (en) 1992-04-10 1995-10-31 Nippon Light Metal Co., Ltd. Electrically heatable caulking system and method
US5686438A (en) 1993-03-09 1997-11-11 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
FR2696934B1 (fr) 1992-10-20 1995-06-02 Conservatoire Nal Arts Metiers Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir.
US5753640A (en) 1995-06-07 1998-05-19 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
CZ193495A3 (en) 1993-03-09 1996-04-17 Univ Utah Res Found The use of dehydroepiandrosterone derivatives for the preparation of a pharmaceutical preparation and pharmaceutical composition containing the derivative
US5635496A (en) 1993-03-09 1997-06-03 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
US5977095A (en) 1993-03-09 1999-11-02 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and respiratory distress syndrome
US5811418A (en) 1993-03-09 1998-09-22 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
US5846963A (en) 1995-06-07 1998-12-08 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
US5840277A (en) 1993-03-30 1998-11-24 Charlotte Hospital Authority Treatment of chronic pulmonary inflammation
DE4311835A1 (de) 1993-04-07 1994-10-13 Boehringer Ingelheim Int Verfahren zur Inhibierung der Transkription von Genen
CA2165777A1 (fr) 1993-06-24 1995-01-05 Junying Yuan Genes et proteines programmes pour la mort des cellules
US5424077A (en) 1993-07-13 1995-06-13 Church & Dwight Co., Inc. Co-micronized bicarbonate salt compositions
US5478566A (en) * 1993-09-29 1995-12-26 Loria; Roger M. Stimulation of cytokine production
US5750336A (en) 1994-02-10 1998-05-12 The Salk Institute For Biological Studies Assays for the identification of compounds which inhibit activation of cAMP and mitogen responsive genes
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
EP0676469A3 (fr) 1994-04-04 1998-03-25 Tadamitsu Kishimoto Facteur de transcription APRF
US5714163A (en) 1994-06-27 1998-02-03 Nexstar Pharmaceuticals, Inc. Vinca alkaloid vesicles with enhanced efficacy and tumor targeting properties
US5658744A (en) 1994-07-22 1997-08-19 The United States Of America As Represented By The Department Of Health And Human Services Methods of identifying patients having an altered immune status
US5792757A (en) 1994-08-04 1998-08-11 Pherin Pharmaceuticals 19-nor-pregnane steroids as neurochemical initiators of change in human hypothalamic function
US5665591A (en) 1994-12-06 1997-09-09 Trustees Of Boston University Regulation of smooth muscle cell proliferation
US6051373A (en) 1994-12-07 2000-04-18 Scriptgen Pharmaceuticals, Inc. Methods for screening for inhibitors of the transcription-enhancing activity of the X protein of hepatitis B virus
US5455049A (en) 1995-01-04 1995-10-03 Ascent Pharmaceuticals, Inc. Terfenadine oral powder
FR2733912B1 (fr) 1995-05-11 1997-07-18 Conservatoire Nat Arts Compositions pharmaceutiques contenant des derives de steroides impliques dans le declenchement de la reponse immunitaire
US5736381A (en) 1995-05-19 1998-04-07 Davis; Roger J. Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
CZ394197A3 (cs) 1995-06-06 1998-06-17 Cocensys, Inc. Neuroaktivní steroidy androstanové a pregnanové řady
US5859000A (en) 1995-06-07 1999-01-12 University Of Utah Research Foundation Method for reducing mast cell mediated allergic reactions
DE69628909T2 (de) * 1995-10-12 2003-12-24 Supergen, Inc. Liposomformulierung von 5-beta steroiden
ATE235505T1 (de) 1995-10-30 2003-04-15 Oleoyl Estrone Developments S Oleat monoester von estrogenen zur behandlung von fettleibigkeit
IT1284853B1 (it) 1996-06-18 1998-05-22 Consiglio Nazionale Ricerche Impiego del 2-ciclopenten-1-one come induttore di hsp70.
WO1997037637A1 (fr) 1996-04-04 1997-10-16 Ortho Pharmaceutical Corporation Formulation topique de vitamine d a base de liposomes
EP0891425A2 (fr) 1996-04-23 1999-01-20 President And Fellows Of Harvard College Procedes et compositions pour la regulation de sous-ensembles de lymphocytes t par la modulation de l'activite du facteur de transcription
US5858711A (en) 1996-11-25 1999-01-12 President And Fellows Of Harvard College NF-AT-interacting protein NIP45 and methods of use therefor
US5958671A (en) 1996-04-23 1999-09-28 Presidents And Fellows Of Harvard College Methods and compositions for regulating T cell subsets by modulating transcription factor activity
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
US6200969B1 (en) 1996-09-12 2001-03-13 Idun Pharmaceuticals, Inc. Inhibition of apoptosis using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
WO1998011877A1 (fr) 1996-09-18 1998-03-26 Dragoco, Inc. Composition de poudre seche contenant un principe actif encapsule dans des liposomes
US5891924A (en) 1996-09-26 1999-04-06 Research Development Foundation Curcumin (diferuloylmethane) inhibition of NFκB activation
US6074850A (en) 1996-11-15 2000-06-13 Canji, Inc. Retinoblastoma fusion polypeptides
US5885977A (en) 1997-01-15 1999-03-23 Humanetics Corporation Use of Δ5 androstenes in the treatment of HIV wasting syndrome
US5869709A (en) 1997-05-07 1999-02-09 Humanetics Corporation Process for effecting allylic oxidation
US5925657A (en) 1997-06-18 1999-07-20 The General Hospital Corporation Use of PPARγ agonists for inhibition of inflammatory cytokine production
US6242253B1 (en) 1997-10-09 2001-06-05 Regents Of The University Of California IkB kinase, subunits thereof, and methods of using same
CA2310632A1 (fr) 1997-11-19 1999-05-27 Humanetics Corporation Utilisation de .delta.5-androstene-3.beta.-ol-7,17-dione dans le traitement du lupus erythemateux
US6174901B1 (en) 1998-12-18 2001-01-16 Amgen Inc. Substituted pyridine and pyridazine compounds and methods of use
US6107034A (en) 1998-03-09 2000-08-22 The Board Of Trustees Of The Leland Stanford Junior University GATA-3 expression in human breast carcinoma
WO1999061008A2 (fr) 1998-05-26 1999-12-02 Peter Louis Carlen Compositions et procedes servant a soulager les fonctions mentales deficientes ou la perte de memoire et a limiter la duree de recuperation chez le mammifere anesthesie
US6248781B1 (en) 1998-10-21 2001-06-19 Novo Nordisk A/S Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR)
AU1230600A (en) 1998-10-28 2000-05-15 President And Fellows Of Harvard College Regulation of th2 cell activity by modulation of nfatp and nfat4 activity
KR100717897B1 (ko) 1999-03-23 2007-05-14 홀리스-에덴 파마슈티칼즈, 인코포레이티드 면역 조절용 스테로이드, 특히16α-브로모에피안드로스테론의 헤미하이드레이트
EP1183355B1 (fr) 1999-06-02 2005-11-02 President And Fellows Of Harvard College Compositions t-bet et methodes d'utilisation de ces compositions
EP1223941B1 (fr) * 1999-10-25 2008-11-05 Hollis-Eden Pharmaceuticals Inc. Traitements therapeutiques pour des deficiences en cellules sanguines par des steroides
US6110691A (en) 2000-01-06 2000-08-29 Board Of Regents, The University Of Texas System Activators of caspases
US6348489B1 (en) 2000-04-11 2002-02-19 Daiichi Pharmaceutical Co., Ltd. Method of treating traumatic brain injury and other neuronal disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO02069977A1 *

Also Published As

Publication number Publication date
AU2008201188A1 (en) 2008-04-03
AU2002244247B2 (en) 2007-12-13
JP2004537506A (ja) 2004-12-16
EP2135611A1 (fr) 2009-12-23
WO2002069977A1 (fr) 2002-09-12
AU2008201188B2 (en) 2011-02-03
CA2439687A1 (fr) 2002-09-12

Similar Documents

Publication Publication Date Title
US7947846B2 (en) 15-OXA-steroid compounds
AU2008201188B2 (en) Use of certain steroids for treatment of blood cell deficiencies
US8022234B2 (en) Compounds and compositions
US20030083231A1 (en) Blood cell deficiency treatment method
US20030060425A1 (en) Immune modulation method using steroid compounds
US6667299B1 (en) Pharmaceutical compositions and treatment methods
US8541600B2 (en) 11-aza, 11-thia and 11-oxa sterol compounds and compositions
AU2002244247A1 (en) Use of certain steroids for treatment of blood cell deficiencies
RU2295534C2 (ru) Полугидрат 16 альфа-бромо-3 бета-гидрокси-5 альфа-андростан-17-он, способ его получения, фармацевтические композиции, применение соединений
AU2005211675B2 (en) Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone
EP1422234A2 (fr) Steroides avec activité d'immunomodulation, surtout le hemihydrat du 16.alpha.-bromoepiandrosterone

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030926

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17Q First examination report despatched

Effective date: 20061128

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20091108